TDP-43, a protein central to amyotrophic lateral sclerosis, is destabilized by tankyrase-1 and -2

McGurk, Leeanne; Rifai, Olivia; Bonini, Nancy M.

Published in:
Journal of Cell Science

DOI:
10.1242/jcs.245811

Publication date:
2020

Document Version
Peer reviewed version

Link to publication in Discovery Research Portal

Citation for published version (APA):
McGurk, L., Rifai, O., & Bonini, N. M. (2020). TDP-43, a protein central to amyotrophic lateral sclerosis, is destabilized by tankyrase-1 and -2. Journal of Cell Science, 133(12). https://doi.org/10.1242/jcs.245811

General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 04. Nov. 2020
TDP-43 a protein central to amyotrophic lateral sclerosis is destabilized by Tankyrase-1/2

Leeanne McGurk1,2*, Olivia Rifai1,3 and Nancy M. Bonini1*.

Affiliations
1Department of Biology, University of Pennsylvania, Philadelphia, PA 19104, USA

2Present address: Cell and Developmental Biology, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK

3Present address: College of Medicine and Veterinary Medicine, University of Edinburgh, Little France Crescent, Edinburgh EH16 4TJ, UK

corresponding authors*
Leeanne McGurk: LMcgurk001@dundee.ac.uk
Nancy M. Bonini: nbonini@ed.ac.uk

Key words: ALS, FTD, PARP, poly(ADP-ribose), proteasome, ubiquitin

Abstract

In >95% of amyotrophic lateral sclerosis (ALS) and ~45% of frontotemporal degeneration (FTD), the RNA/DNA-binding protein TDP-43 is cleared from the nucleus and abnormally accumulates in the cytoplasm of affected brain cells. Although the cellular triggers of disease pathology remain enigmatic, mounting evidence implicates the poly(ADP-ribose) polymerases (PARPs) in TDP-43 neurotoxicity. Here we show that inhibition of the PARP enzymes Tankyrase 1 and Tankyrase 2 (referred to as Tnks-1/2) protect primary rodent neurons from TDP-43-associated neurotoxicity. We demonstrate that Tnks-1/2 interacts with TDP-43 via a newly defined Tankyrase-binding domain. Upon investigating the functional effect, we find that interaction with Tnks-1/2 inhibits the ubiquitination and proteasomal turnover of TDP-43, leading to its stabilization. We further show that proteasomal turnover of TDP-43 occurs preferentially in the nucleus; our data indicate that Tnks-1/2 stabilizes TDP-43 by promoting cytoplasmic accumulation, which sequesters the protein from nuclear proteasome degradation. Thus, Tnks-1/2 activity modulates TDP-43 and is a potential therapeutic target in diseases associated with TDP-43, such as ALS and FTD.
Introduction

Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) are fatal and incurable disorders at two ends of a disease spectrum called ALS/FTD (Gao et al., 2017; Ling et al., 2013). While the full molecular underpinnings of ALS/FTD are unclear, ~5-10% of ALS and 25-50% of FTD is inherited, implicating a genetic cause (Mackenzie and Neumann, 2016; Taylor et al., 2016). Known mutations are enriched in genes with roles in RNA metabolism, autophagy and the ubiquitin proteasome system (UPS) (Balendra and Isaacs, 2018; Gao et al., 2017; Mackenzie and Neumann, 2016; Taylor et al., 2016). Furthermore, at the endpoint of >95% of ALS cases and ~45% of FTD cases, the RNA/DNA-binding protein TDP-43 (TAR DNA-binding protein of 43 kDa) abnormally accumulates in ubiquitin-positive inclusions in the cytoplasm of affected neurons and glia (Arai et al., 2006; Mackenzie et al., 2007; Neumann et al., 2006). Many disease-associated mutations in TDP-43 have been identified in familial and sporadic ALS and occasionally in FTD, implicating TDP-43 dysfunction as central to disease. (Benajiba et al., 2009; Borroni et al., 2009; Floris et al., 2015; Kabashi et al., 2008; Kovacs et al., 2009; Sreedharan et al., 2008; Synofzik et al., 2014; Van Deerlin et al., 2008). Although the ubiquitination and subsequent turnover of TDP-43 has been linked to the UPS and autophagy in cellular systems (Hans et al., 2014; Kim et al., 2009; Liu et al., 2014; Scotter et al., 2014; van Eersel et al., 2011; Winton et al., 2008; Zhang et al., 2010), if and how these degradation pathways regulate the pathobiology of TDP-43 in human disease remains unknown.

Mounting evidence implicates poly(ADP-ribose) (PAR) activity in the neurotoxicity-associated with ALS/FTD and other neurodegenerative disorders such as ischemic stroke, Parkinson’s and Alzheimer’s diseases (Duan et al., 2019; Fatokun et al., 2014; Kam et al., 2018; McGurk et al., 2018a; McGurk et al., 2018b; McGurk et al., 2018c; Naumann et al., 2018; Rulten et al., 2014). PAR is a reversible posttranslational modification generated by PAR polymerases (PARPs) whereby polymers of ADP-ribose are covalently linked onto target proteins (transPARylation) or the enzymes themselves (autoPARylation) (Gupte et al., 2017). An added layer of regulation occurs via non-covalent binding between the PAR polymer and target proteins that harbor PAR-binding domains such as the PAR-binding motif (PBM) (Teloni and Altmeyer, 2016). In mammals there are 4 enzymes with PAR activity: PARP-1, PARP-2, Tankyrase-1 and Tankyrase-2 (Vyas et al., 2014). Of particular interest are the Tankyrases, which are two closely related paralogues, collectively referred to as Tnks-1/2 (Citarelli et al., 2010). Tnks-1/2 both have a PARP domain, a sterile alpha motif (SAM) and 5 Ankyrin-repeat clusters (ARCs) (Citarelli et al., 2010). The SAM domain mediates self-polymerization of Tnks-1/2, which is a biophysical property required for Tnks-1/2 function (De Rycker and Price, 2004; De Rycker et al., 2003; Mariotti et al., 2016).The ARCs bind to a loosely conserved Tankyrase-binding motif (TBM) - RxxΦDG, where x represents any amino acid and Φ is a small hydrophobic amino acid or glycine - that is embedded in target proteins (DaRosa et al., 2018; Guettler et al., 2011; Morrone et al., 2012; Sbodio and Chi, 2002). A central role of Tnks-1/2 is in protein turnover by the UPS (Bhardwaj et al., 2017; Chang et al., 2003; Cho-Park and Steller, 2013; Huang et al., 2009; Levaot et al., 2011; Li et al., 2017b; Zhang et al., 2011).

The first known protein substrate of Tnks-1/2 was the telomere-binding protein TRF1 (Rippmann et al., 2002; Smith et al., 1998). PARylation of TRF-1 releases TRF-1 from DNA resulting in...
telomere elongation (Cook et al., 2002; Smith and de Lange, 2000). PARylated TRF-1 released from telomeres is subsequently ubiquitinated and degraded (Chang et al., 2003). Further involvement of Tnks-1/2 in ubiquitin-mediated proteolysis arose from studies of Axin in the Wnt-signalling pathway (Callow et al., 2011; Croy et al., 2016; Feng et al., 2014; Huang et al., 2009; Zhang et al., 2011). Under basal conditions, Tnks-1/2 PARylates Axin, the PAR polymer recruits an E3-ubiquitin ligase that subsequently ubiquitinates Axin and this directs Axin to the proteasome (Callow et al., 2011; Croy et al., 2016; Feng et al., 2014; Huang et al., 2009; Zhang et al., 2011). However, upon Wnt stimulation, PARylation of Axin stabilizes Axin at the Wnt receptor (Wang et al., 2016; Yang et al., 2016). Tnks-1/2 is known to regulate proteasomal turnover of several other proteins including APC2, 3BP2, HIPPO, PTEN, TRF1 and YAP1 (Bhardwaj et al., 2017; Callow et al., 2011; Chang et al., 2003; Croy et al., 2016; Levaot et al., 2011; Li et al., 2015). The role of Tnks-1/2 and PAR-dependent protein degradation pathways in neurodegenerative diseases such as ALS/FTD is largely unexplored.

Recently, we discovered in Drosophila melanogaster that reduction of the Tnks-1/2 homologue mitigates the neurotoxicity of TDP-43, while upregulation exacerbates TDP-43-associated toxicity (McGurk et al., 2018a). Furthermore, we observed that downregulation of the Tnks-1/2 homologue led to an increase in nuclear TDP-43 and a decrease in cytoplasmic TDP-43 in Drosophila neurons (McGurk et al., 2018a). Given the role of Tnks-1/2 in protein degradation and the role of aberrant protein degradation in ALS/FTD, we sought to determine whether Tnks-1/2 promotes ubiquitination and degradation of TDP-43. We demonstrate that a highly selective inhibitor of Tnks-1/2 activity mitigates the neurotoxicity of TDP-43 to rodent neurons. We uncover that TDP-43 has a functional Tankyrase-binding motif, however our data show that TDP-43 is not degraded by Tnks-1/2-dependent ubiquitination. By contrast, our results suggest that Tnks-1/2 stabilizes TDP-43 and that this may occur by inhibiting degradation of TDP-43 by the nuclear proteasome. These findings provide molecular and cellular insight into the interaction between Tnks-1/2 and TDP-43 and provide a foundation for developing novel therapeutic strategies for TDP-43-associated disease.

RESULTS

Pharmacological inhibition of Tankyrase-1/2 protects against TDP-43-associated toxicity in rodent primary neurons.

Our previous studies demonstrate that Tnks is a dose-sensitive modifier of TDP-43-associated toxicity in Drosophila: upregulation of Tnks enhances TDP-43-associated toxicity while downregulation of Tnks mitigates TDP-43-associated toxicity (McGurk et al., 2018a). In order to ascertain whether Tnks-1/2 inhibition is of therapeutic benefit in mammalian cells, we developed a TDP-43 neurotoxicity assay in rat primary cortical neurons (Fig. 1 A and Fig. S1 A). Primary neurons were virally infected with an attenuated herpes simplex virus encoding either a control protein (LacZ) or human TDP-43. Cultures were maintained for 7d post infection, then immunostained for the neuronal marker Tubulin β-III chain and the surviving neuronal cell bodies were quantified. TDP-43 expression resulted in a significant reduction in cortical neurons compared to the LacZ control (5 moi of virus, 44±2 vs 82 ±26 (st. dev.) neurons, respectively) (Fig. 1, B and C, Fig. S1, B and C, and Fig. S2), indicating that virally induced expression of TDP-43 leads to neuronal toxicity in rat primary cortical neurons.
To determine if Tnks-1/2 inhibition could protect neurons from TDP-43-associated toxicity, we examined the effect of the small-molecule inhibitor G007-LK, as it is highly selective for Tnks-1/2 and has no reported effect on PARP-1 activity (Voronkov et al., 2013). To determine whether treatment with G007-LK had any effect on neurons in the absence of TDP-43-associated toxicity, we treated cultured neurons infected with HSV-LacZ with either vehicle (DMSO) or G007-LK (1µM or 10µM) for 7d and quantified the neuronal cell bodies immunolabelled with Tubulin β-III chain. At the concentrations tested, G007-LK treatment had no significant effect on neuronal number (Fig. 1, B and C, Fig. S1, B and C, Fig. S2), indicating that G007-LK had little to no effect on general neuronal survival. By contrast, neuronal loss induced by HSV-TDP-43 was significantly reduced by treatment with 1µM or 10 µM G007-LK (Fig. 1, B and C, Fig S1, B and C, Fig. S2), indicating that G007-LK protects neurons from TDP-43-associated toxicity. These data demonstrate that treating rat primary cortical neurons with the Tnks-1/2 inhibitor protects against TDP-43-associated toxicity. Furthermore, they suggest that targeting Tnks-1/2 activity in TDP-43-associated disease is a potential therapeutic strategy.

TDP-43 harbors a functional Tankyrase-binding motif

To explore molecular interactions between TDP-43 and Tnks-1/2, including the possibility that TDP-43 and Tnks-1/2 may function together in a protein complex, we established a robust series of co-immunoprecipitation assays in mammalian cells. We consistently observed endogenous TDP-43, and an exogenously expressed wild-type (WT) form of TDP-43 (TDP-43-WT-YFP), to co-immunoprecipitate with endogenous Tnks-1/2 in COS-7 cells and HEK-293T cells (Fig. 2, A and B and Fig. S3, A and B). These data demonstrate that TDP-43 and Tnks-1/2 interact in mammalian protein lysates.

To determine if there was a region within TDP-43 that may directly interact with Tnks-1/2, we computationally aligned the Tankyrase-binding motif (RxxΦDG) to the human TDP-43 protein sequence. This highlighted an evolutionary conserved region (amino acids 165-170) with 84 % identity to the Tankyrase-binding motif (Fig. 2, C-E and Fig. S3 A), which we call the Tankyrase-binding domain (TBD) (Fig. 2 C). To establish if the predicted Tankyrase-binding motif in TDP-43 could mediate an interaction with Tnks-1/2, we deleted the TBD from TDP-43 (TDP-43-ΔTBD-YFP) and tested the ability of the mutant protein to co-immunoprecipitate with Tnks-1/2. This revealed that deletion of the TBD abolished the capacity of TDP-43 to co-immunoprecipitate with Tnks-1/2 in mammalian cells (Fig. 2 F). Importantly, deletion of the TBD did not affect all interactions, as it had no effect on the capacity of TDP-43-ΔTBD to co-immunoprecipitate with endogenous TDP-43 from cellular lysates (Fig. S3 D). Collectively, these data suggest that the TBD is essential for the interaction between TDP-43 and Tnks-1/2.

To further define the Tnks-1/2 interaction domain in TDP-43, we mutated each amino acid in the TBD (RxxΦDG) individually to alanine (Fig. 2 G) and tested the ability of the respective mutated protein variants to co-immunoprecipitate with Tnks-1/2. This demonstrated that mutation of either H166 or I168 to alanine was sufficient to abolish the interaction between TDP-43-YFP and Tnks-1/2, while mutation of R165, D169 and G170 to alanine had little to no effect (Fig. 2 H). We note that the ALS-associated mutation of TDP-43 D169G (Kabashi et al., 2008) resides within the TBD of TDP-43; however, similar to the alanine mutation in D169, the mutation to glycine had no effect on the co-immunoprecipitation of TDP-43 with Tnks-1/2 (Fig. S3 E).
Analysis of the previously solved NMR structure of RRM1 and RRM2 of TDP-43 (Lukavsky et al., 2013) revealed that the TBD and the RNA-binding regions are on opposite sides of RRM1 (Fig. 2 I). Recent studies have also demonstrated that mutation in the TBD region (D169G) has no effect on RNA-binding (Chen et al., 2019). The TBD spans a loop, a β-strand and a second loop (Fig. 2 J) and intriguingly, the amino acids essential for the interaction with Tnks-1/2 (H166 and I168) are positioned on the internal side of the β-strand (Fig. 2 J). The non-essential amino acids of the TBD are located on the unstructured loops (R165, D169 and G170) or on the external surface of the β-strand (M167) (Fig. 2 J). These combined data indicate that TDP-43 and Tnks-1/2 interact and that this interaction is dependent upon H166 and I168 which are positioned in the β-strand of TBD of TDP-43.

Tankyrase-1/2 inhibits ubiquitination and proteasomal turnover of TDP-43

The ADP-ribosylation activity of Tnks-1/2 has been established to promote proteasomal turnover of Tnks-1/2 substrates including APC2, Axin, 3BP2, HIPPO, PTEN, TRF1 and YAP1 (Bhardwaj et al., 2017; Callow et al., 2011; Chang et al., 2003; Croy et al., 2016; Huang et al., 2009; Levao et al., 2011; Li et al., 2015). To test the possibility that Tnks-1/2 may regulate the levels of TDP-43, we treated cells with the protein-synthesis inhibitor cycloheximide and measured the degradation of endogenous TDP-43 in the presence of vehicle (DMSO) or the Tnks-1/2 inhibitor XAV939. Surprisingly, treatment with XAV939 led to a slight but significant decrease \( (p < 0.0013) \) in the levels of endogenous TDP-43 protein compared to the vehicle control (Fig. 3 A-B). This finding indicates that inhibition of Tnks-1/2 promotes the degradation of endogenous TDP-43. To rule out potential off-target effects of the Tnks-1/2 inhibitor, we compared the degradation of TDP-43-WT-YFP to the forms of TDP-43-YFP unable to interact with Tnks-1/2 (TDP-43-ΔTBD, -H166A and -I168A). Consistent with the effect of the Tnks-1/2 inhibitor on endogenous TDP-43 (Fig. 3 A and B), the levels of TDP-43-YFP unable to interact with Tnks-1/2 (TDP-43-ΔTBD, -H166A and -I168A) were significantly reduced \( (p < 0.0009) \) compared to TDP-43-YFP that interacts with Tnks-1/2 (TDP-43-WT, -R165A, -M167A, -D169A and -G170A) (Fig. 3, C-F and Fig. S4). Together, these data indicate that loss of the Tnks-1/2 interaction leads to increased degradation of TDP-43 and suggest that under normal conditions Tnks-1/2 functions to stabilize TDP-43.

Given that Tnks-1/2 stabilized TDP-43 (Fig. 3), we examined the ubiquitination levels of TDP-43 upon proteasome inhibition. To do this we treated cells with control (DMSO) or the proteasome inhibitor MG132 for 2 hr or 4 hr, then immunoprecipitated either TDP-43-WT-YFP or TDP-43-ΔTBD-YFP and probed for ubiquitin conjugation. This showed a significant increase in ubiquitinated TDP-43-WT after 4 hr of MG132 treatment (Fig. 4, A-C). By contrast, a significant increase in MG132-induced ubiquitination of TDP-43-ΔTBD was detected after only 2 hr of treatment (Fig. 4, A-C), indicating that TDP-43-ΔTBD is more rapidly ubiquitinated than TDP-43-WT. To test if pharmacological inhibition of Tnks-1/2 regulates MG132-induced ubiquitination of TDP-43-WT-YFP, we treated cells with G007-LK, a highly selective inhibitor of Tnks-1/2 activity with no effect on PARP-1 (Voronkov et al., 2013). Consistent with TDP-43-ΔTBD being more rapidly ubiquitinated than TDP-43-WT (Fig. 4, A-C), treatment with the Tnks-1/2 inhibitor G007-LK significantly increased the levels of MG132-induced ubiquitination of TDP-43-WT compared to the control (Fig. 4, D-F). A second Tnks-1/2 inhibitor, XAV939, behaved similarly (Fig. S5, A-C). The effect of Tnks-1/2 inhibition on MG132-induced ubiquitination of TDP-43 was not additive, as treatment with the Tnks-1/2 inhibitor alone did not lead to ubiquitination of
TDP-43-WT-YFP (Fig. S6, A and B). Collectively, these data demonstrate that loss of the Tnks-1/2 interaction or reduced Tnks-1/2 activity promotes MG132-induced ubiquitination of TDP-43 and increases proteasomal degradation of the protein. Thus, our data suggest that Tnks-1/2 maintains TDP-43 in a non-ubiquitinated and stabilized state.

**Proteasomal turnover of TDP-43 occurs in the nucleus.**

To gain an understanding of how Tnks-1/2 may lead to stabilization of TDP-43, we examined TDP-43 localization by immunofluorescence. Under normal conditions, both TDP-43-WT-YFP and TDP-43-ΔTBD-YFP localized diffusely to the nucleus. In response to MG132 treatment, both proteins formed nuclear foci that co-labelled with ubiquitin (Fig. 5, A and B). However, ubiquitin co-labelling occurred significantly earlier for nuclear TDP-43-ΔTBD foci than for TDP-43-WT foci (2 hr vs 4 hr of treatment) (Fig. 5, A and B). These data are consistent with our finding that TDP-43-ΔTBD is more rapidly ubiquitinated than TDP-43-WT (see Fig. 4), and indicates that upon proteasome inhibition, both TDP-43 proteins (WT and ΔTBD) accumulate in ubiquitin-positive foci in the nucleus.

Curiously, we observed that MG132 treatment did not lead to an increase in the percentage of cells with cytoplasmic foci of TDP-43-WT or TDP-43-ΔTBD, or with cytoplasmic foci of the protein co-labelled with ubiquitin (Fig. 5, A and C). This appears to be in contrast to some studies, but consistent with others, and we suggest this difference is due to the time period of MG132 treatment (see Discussion). This result, however, raised the possibility that proteasome inhibition may preferentially promote accumulation of TDP-43 selectively in the nucleus. To further explore proteasomal-turnover of TDP-43 in the context of the cellular milieu, we examined the effect of MG132 on a form of TDP-43 that cannot be imported into the nucleus and instead localizes to the cytoplasm. TDP-43 nuclear localization is dependent upon a bipartite nuclear localization sequence (NLS) that also acts as a PAR-binding motif (PBM) in the N-terminal portion of the protein (Fig. S7A); mutation of this region (TDP-43-ΔNLS/PBM) prevents nuclear import and binding to PAR (McGurk et al., 2018a; Winton et al., 2008). Under conditions in which MG132 treatment increased the percentage of cells with nuclear TDP-43-WT-GFP foci (from 9.4±1.3% to 45±3.6% (s.e.m.)), TDP-43-ΔNLS/PBM-GFP remained diffusely cytoplasmic (Fig. 6, B and D and Fig. S7, B-D). It is important to note that under the same conditions, the cytoplasmic protein G3BP1 formed cytoplasmic foci in response to MG132 treatment (Fig. S8, A and B), which is consistent with previous reports (Mazroui et al., 2007). Thus, our data suggest that under the conditions tested, TDP-43 localized to the cytoplasm (TDP-43-ΔNLS/PBM) does not respond to MG132.

To determine if TDP-43-ΔNLS/PBM remained diffuse upon MG132 treatment because of its cytoplasmic localization or, alternatively, because the NLS/PBM mutation impaired the ability of the protein to respond to proteasome inhibition, we generated TDP-43-ΔNLS/PBM-GFP with an exogenous NLS sequence. We compared the bipartite NLS/PBM from the TDP-43 protein (TDP-43-ΔNLS/PBM-ΔTDP-43) to the proline-tyrosine NLS (PY-NLS) from hnRNPA1 (TDP-43-ΔNLS/PBM-ΔA1) (Fig. S7 A). The NLS from TDP-43 differs from the PY-NLS not only in amino acid sequence but also in the transport system used to direct proteins to the nucleus. Importin α/β (also known as Karyopherin α/β1) directs TDP-43 to the nucleus while Transportin (also known as Karyopherin β2 directs hnRNPA1 to the nucleus (Lee et al., 2006; Winton et al., 2008). Under
normal conditions TDP-43-ΔNLS/PBM-TDP-43 and TDP-43-ΔNLS/PBM-A1 localized to the nucleus (Fig. 6 A) and upon treatment with MG132, both TDP-43-ΔNLS/PBM-TDP-43 and TDP-43-ΔNLS/PBM-A1 formed ubiquitin-labelled nuclear foci (Fig. 6, B, C and D). These data suggest that TDP-43 must be in the nucleus to form MG132-induced nuclear foci. These data also suggest that the NLS/PBM sequence of TDP-43 is not required for the response to MG132 treatment, because the addition of a different NLS sequence (TDP-43-ΔNLS/PBM-A1) also rescues MG132-induced accumulation of the protein.

To gain a molecular understanding of TDP-43 turnover in the context of the cell, we assessed the ubiquitination levels of immunoprecipitated TDP-43-GFP localized to the nucleus (-WT, -NLS/PBM-TDP-43) or cytoplasm (-ΔNLS/PBM). Upon MG132 treatment, both nuclear forms of TDP-43 (-WT and -ΔNLS/PBM-TDP-43) were ubiquitinated (Fig. 6, E and F). Although MG132 treatment led to an increase in ubiquitination of cytoplasmic TDP-43 (-ΔNLS/PBM) compared to baseline, the levels were significantly lower than for TDP-43-WT (Fig. 6, E and F). This finding indicates that upon MG132 treatment, ubiquitinated TDP-43-GFP localized to the nucleus accumulates more rapidly than ubiquitinated TDP-43-GFP in the cytoplasm. These data further suggest that in this assay TDP-43 is preferentially degraded by the nuclear proteasome.

**Tankyrerase-1/2 promotes cytoplasmic accumulation of TDP-43**

Previously, we found that Tnks-1/2 regulates the cytoplasmic accumulation of TDP-43 in aging neurons in *Drosophila* and in the cytoplasm of mammalian cells exposed to the chemical stressor arsenite (McGurk et al., 2018a). Furthermore, Tnks-1/2 has been reported to localize to the cytoplasmic face of the nuclear pore complex (Smith and de Lange, 1999). We thus considered that Tnks-1/2 may inhibit turnover of TDP-43 by promoting cytoplasmic accumulation of the protein. To explore this possibility, we examined the localization of TDP-43-WT-GFP in cells treated with highly selective Tnks-1/2 inhibitors (G007-LK and IWR1-endo) that have no reported effect on PARP-1 (Huang et al., 2009; Voronkov et al., 2013). Under control conditions, TDP-43-WT was observed in the cytoplasm of 19.5±2% (s.e.m) of cells (Fig. 7, A and B), and treatment with the Tnks-1/2 inhibitors G007-LK or IWR1-endo significantly (*p* = 0.0032) reduced the percentage of cells with observable cytoplasmic TDP-43-WT (from 19.5±2% to 10.7±0.6% and 9.6±0.7% (s.e.m), respectively) (Fig. 7, A and B ). A third inhibitor of Tnks-1/2, XAV939, also reduced the percentage of cells with TDP-43-WT in the cytoplasm (Fig. 7 C). Combined, these data indicate that under non-stressed conditions, Tnks-1/2 activity promotes cytoplasmic accumulation of TDP-43-WT. Furthermore, we suggest that, by promoting cytoplasmic accumulation of TDP-43, Tnks-1/2 indirectly inhibits TDP-43 degradation by the nuclear proteasome (Fig. 8), leading to its stabilization.

**DISCUSSION**

We have uncovered, in mammalian cells, that TDP-43 and Tnks-1/2 proteins interact through a newly defined Tankyrase-binding domain in TDP-43. Unlike previously established Tnks-1/2 substrates such as Axin, this interaction does not promote ubiquitination and degradation of TDP-43. Instead, the interaction with Tnks-1/2 stabilizes TDP-43, potentially by promoting the cytoplasmic localization of TDP-43. Our data also suggest that ubiquitinated TDP-43 preferentially accumulates in the nucleus where it can be degraded by the nuclear proteasome. In the context of ALS/FTD, Tnks-1/2 inhibitors, and potentially inhibitors specific for the TDP-43
and Tnks-1/2 interaction, could help maintain TDP-43 in the nucleus, where damaged and misfolded forms of the protein can be turned over by the proteasome. Consistent with this, we demonstrate that pharmacological inhibition of Tnks-1/2 activity protects against TDP-43-associated neurotoxicity in primary rodent neurons.

The Tankyrase-binding motif is a loosely conserved motif of RxxΦDG (Guettler et al., 2011; Sbodio and Chi, 2002). The first and last amino acid (R1 and G6) in peptides or fragments that span the Tankyrase-binding motif of 3BP2, Axin1, RNF146 and IRAP abolish the interaction with Tnks-1/2 and are considered to be invariant amino acids (DaRosa et al., 2018; Guettler et al., 2011; Morrone et al., 2012; Sbodio and Chi, 2002). Mutation analysis of a peptide spanning the TBD of 3BP2 demonstrated that at position 4, glycine, proline, alanine and cysteine are preferred while isoleucine, leucine and valine prevent Tnks-1/2 binding to the 3BP2 peptide (Guettler et al., 2011). This appears in contrast with our detailed mutational analysis of the Tankyrase binding domain in TDP-43, which show that mutation of R1 or G6 has little to no effect on the interaction between TDP-43 and Tnks-1/2. Furthermore, not only is position 4 of the TBD an isoleucine, mutation of this amino acid in the full-length form of TDP-43 abolishes the interaction with Tnks-1/2. Thus, we suggest that TDP-43 may harbour a Tankyrase-binding motif with non-canonical features. It is important to note that non-canonical and extended Tankyrase-binding motifs have been identified; these include an extra 2 amino acids after position 6 in 3BP2 and motifs with additional amino acids between position 1 and 2 in APC2, Axin1 and RNF146 (Croy et al., 2016; DaRosa et al., 2018; Guettler et al., 2011; Morrone et al., 2012). Furthermore, the second Tankyrase-binding motif in Axin is not dependent on R1 (Morrone et al., 2012) and Tankyrase-binding motifs in several other proteins harbor amino acids that are not tolerated at the fourth position in the 3BP2 peptide including a valine (motif 1 of Axin 1, motif 2 in RNF146, motif 1 of APC2 and motif 3 of PEX14) and a leucine (motif 2 of MDC1) (Croy et al., 2016; DaRosa et al., 2018; Li et al., 2017b; Morrone et al., 2012; Nagy et al., 2016). Thus, in the context of different proteins or perhaps context-dependent functions of Tnks-1/2, the constraints on the consensus of the Tankyrase-binding motif differ.

Functionally, Tnks-1/2 has a central role in PARylation-dependent ubiquitination, a process that can lead to proteasomal degradation of target proteins such as Axin, 3BP2, HIPPO, PARP-1, PTEN, TRF1 and YAP1 (Bhardwaj et al., 2017; Callow et al., 2011; Chang et al., 2003; Croy et al., 2016; Feng et al., 2014; Huang et al., 2009; Levaot et al., 2011; Li et al., 2015; Zhang et al., 2011). Surprisingly, our studies suggest that Tnks-1/2 stabilizes TDP-43. These results encompass pharmacological inhibition of Tnks-1/2 activity on endogenous TDP-43 protein, and expression of exogenous TDP-43-WT-YFP forms with mutational variants unable to associate with Tnks-1/2 (-ΔTBD, -H166 and -I168). Although our findings may appear in contrast to the examples of Tnks-1/2 promoting PAR-dependent proteolysis, it is important to note that upon Wnt stimulation, Tnks-1/2 function stabilizes Axin at the cell membrane, promoting the association of Axin with the Wnt receptor (Wang et al., 2016; Yang et al., 2016). Thus, the finding that the Tnks-1/2 homologue is a dose-sensitive modifier of TDP-43 neurotoxicity in Drosophila (McGurk et al., 2018a) may in part be explained by the ability of Tnks-1/2 activity to stabilize TDP-43 protein levels.

The mechanism by which Tnks-1/2 stabilizes TDP-43 may include cellular localization of the protein. Using a combination of biochemistry and immunofluorescence, we observed that upon proteasome inhibition, TDP-43 primarily accumulates in the nucleus and is more rapidly
ubiquitinated than cytoplasmic TDP-43. Our data, presented here and previously (McGurk et al., 2018a), suggest that Tnks-1/2 promotes cytoplasmic accumulation of TDP-43. We hypothesize that in doing so, Tnks-1/2 may either sequester TDP-43 from the nuclear proteasome or inhibit nuclear import of the protein which ultimately leads to stabilization (Fig. 8). Tnks-1/2 activity is known to regulate protein localization, for example by promoting Axin localization to the Wnt receptor, or alternatively by directing its degradation (De Rycker and Price, 2004; Mariotti et al., 2016; Wang et al., 2016; Yang et al., 2016). Whether the regulation of TDP-43 localization by Tnks-1/2 is direct or indirect, and whether this involves modification of TDP-43, for example by PARylation, remain to be established.

Impairment of the proteasome has been hypothesized to be a disease-causing mechanism in ALS/FTD (Scotter et al., 2015; Taylor et al., 2016), thus many studies have examined TDP-43 cellular localization upon proteasome inhibition with MG132. Treatment with MG132 for extended time periods (ranging from 12 hr to 72 hr) leads to diffuse accumulation of TDP-43 in the cytoplasm (Klim et al., 2019; van Eersel et al., 2011; Walker et al., 2013) or cytoplasmic aggregates of TDP-43 (Huang et al., 2014; Li et al., 2017a; Scotter et al., 2014). Our data demonstrate that treatment with MG132 for short periods of time (3-5 hr) leads to nuclear foci formation of TDP-43-WT, while TDP-43 localized to the cytoplasm (TDP43-ΔNLS/PBM) remains diffuse. Our findings are consistent with previous studies that show that TDP-43-WT forms nuclear foci in cells treated with MG132 for 8 hr (Wang et al., 2010) and that TDP-43 with mutation the NLS/PBM remains diffuse upon treatment with MG132 for 6 hr (Nonaka et al., 2009). Thus, we propose that upon proteasomal inhibition, TDP-43 accumulation in the nucleus occurs earlier than in the cytoplasm. Our data further suggest that turnover of TDP-43 by the nuclear proteasome is important for regulating TDP-43 degradation.

An impact on global protein levels is thought to be involved in in ALS/FTD. Many disease-associated mutations occur in proteins that function in protein turnover such as the UPS and autophagy, including C9orf72, Charged multivesicular body protein 2b, Optineurin, Sequestrome 1, Serine/Threonine-protein Kinase TBK1, Ubiquilin 2 and VCP, suggesting a broad impairment of protein turnover in neurodegenerative disease (Balendra and Isaacs, 2018; Gao et al., 2017; Taylor et al., 2016). Furthermore, altered TDP-43 protein levels has also been implicated in disease. For example, TDP-43 mRNA levels are upregulated in post-mortem tissue from patients with ALS/FTD as well as in a knock-in mouse model for the Q331K disease-causing mutation in TDP-43 (Gitcho et al., 2009; Mishra et al., 2007; White et al., 2018). In post-mortem tissue, TDP-43 protein abnormally accumulates in ubiquitin inclusions in the cytoplasm of affected neurons and glia, suggesting that the affected cells cannot remove and degrade TDP-43 in the cytoplasm (Arai et al., 2006; Mackenzie et al., 2007; Neumann et al., 2007). In patient fibroblasts (sporadic and those harboring a G4C2-hexanucleotide expansion in C9orf72 or mutation in TDP-43), the levels of cytoplasmic TDP-43 and levels of total TDP-43 protein compared to control cells are significantly higher (Lee et al., 2019; Sabatelli et al., 2015). Additionally, upon proteasome inhibition, TDP-43 protein levels remain unaltered in these ALS/FTD patient fibroblasts (Lee et al., 2019), suggesting that UPS turnover of TDP-43 is impaired. It is intriguing to postulate that UPS-mediated turnover of TDP-43 is impaired in the ALS/FTD patient fibroblasts because TDP-43 is accumulating in the cytoplasm and thus is sequestered from the nuclear proteasome.
There are no effective treatments for ALS/FTD and related disorders such as Parkinson’s disease. In ALS, nuclear PAR is elevated in motor neurons of post-mortem spinal cord tissue and total PAR is elevated in the cerebrospinal fluid of patients with Parkinson’s disease (Kam et al., 2018; McGurk et al., 2018c). These findings suggest that inhibiting PARP activity may have therapeutic potential. Similar to inhibition of Tnks-1/2, chemical inhibition of nuclear PARP-1/2 activity reduces accumulation of TDP-43 in stress foci in the cytoplasm (McGurk et al., 2018a). Thus, nuclear PARP activity may promote nuclear export of TDP-43, which may also lead to reduced turnover of the protein. Finding agents that regulate the levels of TDP-43 is important to modulate TDP-43 protein homeostasis, as well as to remove misfolded and possibly toxic forms of the protein that accumulate in affected brain regions. We propose that inhibition of Tnks-1/2, which regulates TDP-43 stability and neurotoxic properties, is a potential therapeutic target for ALS/FTD and related disorders.

Methods

**Rat cortical neurons culture and neurotoxicity assays.**

Rat cortical neurons were from embryos isolated from female Sprague Dawley wild rats that were 16-18 days pregnant (Neuron R Us, neuron service center, University of Pennsylvania). 100,000 neurons were plated out on poly-D-lysine coated coverslips (12mm diameter and thickness #1 (Neuvitro, Vancouver, WA, Canada) in neurobasal medium (ThermoFisher Scientific, Waltham, MA, USA) supplemented with serum-free B27 (ThermoFisher Scientific, Waltham, MA, USA), penicillin streptomycin (ThermoFisher Scientific, Waltham, MA, USA) and Glutamax (ThermoFisher Scientific, Waltham, MA, USA). Neurons were cultured at 37°C with 5% CO2 and half of the media was removed and replaced with fresh prewarmed media 3 times per week. The primary neurons were infected at 14-17 DIV with HSV-TDP-43 or HSV-LacZ with either the Tnks-1/2 inhibitor G007-LK (SelleckChem, Houston, TX, USA) or DMSO (Sigma Aldrich, St. Louis, MI, USA). Every 2d, half of the media was removed and replaced with fresh media containing the G007-LK or DMSO. The drug containing media was made up twice concentrated so that when it was diluted 2-fold in the well it was of the appropriate concentration. 7d post infection, the neurons were fixed in 4% paraformaldehyde, blocked in 10% normal donkey serum (Sigma Aldrich, St. Louis, MI, USA) in Tris buffered saline with 0.05% Tween® 20 (TBST) (ThermoFisher Scientific, Waltham, MA, USA) for 1 hr at room temperature, and immunostained overnight at 4°C with antibodies directed to the neuronal marker Tubulin β-3 chain (1 in 500, Abcam, Cambridge, UK). After 3 sets of 5 min washes in TBST (ThermoFisher Scientific, Waltham, MA, USA) neurons were incubated with mouse AlexaFluor 488 (1 in 500, ThermoFisher Scientific, Waltham, MA, USA) in the dark for 1hr at room temperature. Neurons were washed with TBST 3 times (5 min each) and counterstained with 1 µg/ml Hoechst-33342 (ThermoFisher Scientific, Waltham, MA, USA) (15 min), washed in deionized H2O and mounted in prolong diamond (ThermoFisher Scientific, Waltham, MA, USA). Five images (10X magnification) were captured from each coverslip and remaining neuronal cell bodies in each image were counted. Each condition was repeated three times, on three independent cultures each from a different pregnant rat.

**Mammalian cells and culture details**

COS-7 cells originally purchased by ATCC were a gift from Virginia M. Lee (University of Pennsylvania). Prior to purchase the COS-7 cells were authenticated by ATCC.
HEK293T cells were kindly provided by Aaron Gitler (Stanford University). COS-7 cells were routinely grown in Dulbecco’s modified Eagle’s medium with high glucose and L-glutamine (ThermoFisher Scientific, Waltham, MA, USA), 10% filter sterile FBS (Sigma Aldrich) and penicillin-streptomycin (ThermoFisher Scientific, Waltham, MA, USA). HEK-293T cells were grown in DMEM with high glucose, L-glutamine and sodium pyruvate (ThermoFisher Scientific, Waltham, MA, USA), 10% filter sterile FBS (Sigma Aldrich, St. Louis, MI, USA) and penicillin-streptomycin (ThermoFisher Scientific). Cells were grown at 37°C with 5% CO₂, and a water bath was used for humidification. Cells were washed with dPBS without calcium and without magnesium (ThermoFisher Scientific, Waltham, MA, USA) and trypsinized in Trypsin with 0.25% EDTA (ThermoFisher Scientific, Waltham, MA, USA). No commonly misidentified cell lines were used.

Identification of the Tankyrase binding domain

We computationally aligned the Tankyrase-binding motif (RxxΦDG) to the human TDP-43 protein sequence using the PATTINPROT search engine (Combet et al., 2000). To map the TBD to the reported NMR structure of RRM1 and RRM2 of TDP-43 (4BS2) 43 (Lukavsky et al., 2013) we used the open source Java viewer “FirstGlance in Jmol”.

Plasmids

Human TDP-43-WT-YFP in pcDNA3.2 was described previously (Elden et al., 2010). TDP-43-WT-GFP and TDP-43-ΔPBM both in pcDNA3-C-eGFP were described previously (McGurk et al., 2018a). The NES-GFP (NES-MS2-coat protein-GFP) and NLS-GFP (NLS-MS2-coat protein-GFP) in pGW were described previously (Burguete et al., 2015).

TDP-43-ΔTBD, -D169G, -R165A, H166A, M167A, I168A, D169A and G170A were made by performing site directed mutagenesis (QuikChange II XL) on TDP-43-WT-YFP using the following forward primers (FP) and reverse primers (RP):

ΔTBD FP 5’ CAAGTGAAAGTAATGTCACACGCCATGTTGACTGCAAACCTTC 3’
ΔTBD RP 5’ GGAAGTTTGCAGTCACACCACATCGCTGACATTTCTTACTTC 3’
D169G FP 5’ TCACACGCCACATGATAGGTTGACAGTGTGGACTG 3’
D169G RP 5’ GCACTGAACCATCGCCACCATATCATTAGTCTGCTGTA 3’
R165A FP 5’ CATCGTCCATCTCATATGTGCCTGACATTACTTTTCACTT 3’
R165A RP 5’ CAAGTGAAGTAATGTCACACGCGAGCTATGAGATGAGACGATG 3’
H166A FP 5’ CACCAGTTCCATCTCATATCTAGCTCGCTGACTGCAACTTTTC 3’
H166A RP 5’ GTGAAAGTAATGTCACACGCCAGCTATGAGATGAGACGATG 3’
M167A FP 5’ CACACACCACATCGCCACCATATCTGAGCTCGCTGACATTACTT 3’
M167A RP 5’ UCAGTGAAGTAATGTCACACGCCAGCTATGAGATGAGACGATG 3’
I168A FP 5’ GTCAACACCATGTTCCATCTTGCAATATGTCACGTGACATT 3’
I168A RP 5’ AGTGTCACACGCCAGCATGAGCAGATGAGACGATG 3’
D169A FP 5’ GTCAACACCATGTCCTGACCTATGACATGAGACGATG 3’
D169A RP 5’ ACAGTGAAATGTCACACGCCAGCTGAGACGATG 3’
G170A FP 5’ TGCAAGTCAACACCATGTCCTGACCTATGACATGAGACGATG 3’
G170A RP 5’ GCCACATGATGAGCAGATGAGACGATG 3’
The DNA sequence corresponding to the NLS of TDP-43 (TDP-43-\(\Delta\)PBM-NLS\_TDP-43) or the NLS of hnRNPA1 (TDP-43-\(\Delta\)PBM-NLS\_A1) was cloned immediately upstream of the stop site in TDP-43-\(\Delta\)PBM-GFP in pcDNA3-C-eGFP by GenScript, Piscataway, NJ, USA. The DNA sequences subcloned were:

TDP-43-\(\Delta\)PBM-NLS\_TDP-43: 5’ AAA AGA AAA ATG GAT GAG ACA GAT GCT TCA TCA GCA GTG AAA GTG AAA AGA 3’

TDP-43-\(\Delta\)PBM-NLS\_A1: 5’ AAT CAG TCT TCA AAT TTT GGA CCC ATG AAG GGA GGA AAT TTT GGA GCC AGA AGC TCT GGC CCC TAT GGC GGT GGA GGC CAA TAC TTT GCA AAA CCA CGA AAC CAA GGT GGC TAT 3’

All plasmid inserts were sequenced and confirmed to be free of any errors.

Co-immunoprecipitation and Immunoblotting
To examine the interaction between endogenous TDP-43 and Tnks-1/2, 2.5 µg of control mouse IgG (Santa Cruz Biotechnology, Dallas, TX, USA) and 2.5 µg mouse anti-TDP-43 (5028) (Kwong et al., 2014) were coupled to 50 µl Protein G dynabeads\textsuperscript{TM} (ThermoFisher Scientific, Waltham, MA, USA). COS-7 and HEK293T cells were each grown to confluency in 1 T75 flask overnight and lysed the following day. See below for lysis method. For co-immunoprecipitation of transfected TDP-43-YFP and endogenous Tnks-1/2, 2.5 µg mouse IgG (Santa Cruz Biotechnology, Dallas, TX, USA) and 2.5 µg mouse anti-GFP (3E6, ThermoFisher Scientific, Waltham, MA, USA) were coupled to 50 µl Protein G dynabeads\textsuperscript{TM} (ThermoFisher Scientific, Waltham, MA, USA). COS-7 and HEK293T cells were each seeded at a density of 2.7 x 10\(^6\) cells in 1 T75 flask overnight. T75 Flasks were transfected with 8 µg plasmid DNA, 8 µl PLUS reagent and 28 µl LTX in 1600 µl OPTIMEM I in DMEM with high glucose and L-glutamine (all ThermoFisher Scientific, Waltham, MA, USA) and 10% FBS (Sigma Aldrich, St. Louis, MI, USA). For all experiments cells were trypsinized in Trypsin with 0.25 % EDTA (ThermoFisher Scientific, Waltham, MA, USA) and cells were pelleted, washed in Dulbecco’s PBS without calcium and without magnesium (ThermoFisher Scientific, Waltham, MA, USA) and resuspended in 1 mL ice-cold Pierce IP Lysis Buffer (ThermoFisher Scientific, Waltham, MA, USA) containing Halt Protease Inhibitor Single-Use Cocktail (ThermoFisher Scientific, Waltham, MA, USA). For all co-immunoprecipitations lysates each from 1 T75 flask (~8.4 x 10\(^6\) cells) , were incubated on ice for 10 min, passed through a 20G1½ 1 mL syringe (BD Biosciences, San Jose, CA, USA) 3 times, transferred to centrifuge tubes, rotated at 15 rpm for 10 min at 4°C and centrifuged for 10 min at 15000 rpm at 4°C. The supernatant was collected, and pellet discarded, 25 µl of lysate was removed for input and the remaining lysate was divided in half (500 µl) for incubation with IgG or anti-TDP-43-coupled beads. The reactions were made up to 1 mL in lysis buffer with protease inhibitor and incubated with the antibody-coupled beads for 18 hr at 4°C with 15 rpm rotation. The beads were washed 3 times by removing the supernatant, adding 500 µl lysis buffer containing protease inhibitor, briefly resuspending the beads, placing the tube on the magnet and immediately removing the buffer. Elution was performed at 95°C for 5 min in 40 µl 1X LDS Sample Buffer (ThermoFisher Scientific, Waltham, MA, USA) with 5% \(\beta\)-mercaptoethanol (Sigma Aldrich). Input samples (10 µl) were denatured at 95°C for 5 min in 1X LDS Sample Buffer (ThermoFisher Scientific, Waltham, MA, USA) with 5% \(\beta\)-mercaptoethanol (Sigma Aldrich, St. Louis, MI, USA) in a total volume of 20 µl.
Eluates and inputs were electrophoresed (10 µl of the eluate and 10 µl of input was loaded for the detection of TDP-43, and 13 µl of the eluate and input for the detection of Tnks-1/2) on NuPAGE 4-12% Bis-Tris gels (ThermoFisher Scientific, Waltham, MA, USA) in NuPAGE MES or MOPS Buffer (ThermoFisher Scientific, Waltham, MA, USA). Protein was transferred onto 0.45 µm nitrocellulose membranes (BioRad) using the XCell II Blot Module (ThermoFisher Scientific), in 1X Transfer Buffer (ThermoFisher Scientific, Waltham, MA USA) at 20V for 105 min. Membranes were blocked in Tris buffered saline with 0.05% Tween® 20 (TBST) (ThermoFisher Scientific, Waltham, MA, USA) with 5% non-fat dry milk (LabScientific, Danvers, MA, USA) for 1 hr at room temperature, then incubated in primary antibody in TBST (ThermoFisher Scientific, Waltham, MA, USA) overnight at 4°C. Membranes were washed 5 x 5 min in TBST, incubated in secondary antibody in TBST for 1 hr at room temperature, washed 5 x 5 min in TBST and covered in ECL Prime detection reagent (Amersham, Little Chalfont, UK) for 5 min in the dark. Rabbit anti-TDP-43 (1:10,000; Proteintech, Rosemont, IL, USA, Cat# 10782-2-AP, RRID: AB_615042), rabbit anti-Tnks-1/2 (1:500; Santa Cruz Biotechnology, Dallas, TX, USA Cat# sc-8337, RRID:AB_661615) and goat anti-rabbit HRP (1:5000; EMD Millipore, Burlington, MA, USA Cat# 115-035-146, RRID:AB_11212848) were used.

**Immunoprecipitation and Immunoblotting**

COS-7 cells were seeded at a density of 2.7 x 10⁵ cells in a 6-well plate overnight in DMEM with high glucose and L-glutamine (ThermoFisher Scientific, Waltham, MA USA), 10% FBS (Sigma Aldrich, St. Louis, MI, USA) and penicillin-streptomycin (ThermoFisher Scientific, Waltham, MA, USA). Each well was transfected with 2.5 µg plasmid DNA, 2.5 µl PLUS reagent and 7.9 µl LTX in 400 µl OPTIME M I (all ThermoFisher Scientific, Waltham, MA, USA) in DMEM with high glucose (ThermoFisher Scientific, Waltham, MA, USA) and 10% FBS (Sigma Aldrich, St. Louis, MI, USA). 2.5 µg of control IgG (Santa Cruz Biotechnology, Dallas, TX, USA) and 2.5 µg anti-GFP-3E6 (ThermoFisher Scientific, Waltham, MA, USA) were coupled to 50 µl Protein G dynabeads™ (ThermoFisher Scientific, Waltham, MA, USA). For MG132-induced ubiquitin of TDP-43, cells were treated with 10 µM MG132 (Sigma Aldrich, St. Louis, MI, USA) or equivalent volume DMSO (Sigma Aldrich, St. Louis, MI, USA) 23 hr post-transfection for the indicated times. Treatment with the DMSO control always matched the longest MG132 treatment. For MG132-induced ubiquitination of TDP-43 in the presence or absence of Tnks-1/2 inhibitor cells were treated with 10 µM MG132 (Sigma Aldrich, St. Louis, MI, USA) combined with either DMSO (Sigma Aldrich, St. Louis, MI, USA) or XAV939, G007-LK or IWR1-endo (all SelleckChem, Houston, TX, USA) at the indicated times and concentrations. Cells were lysed by adding 300 µl ice-cold RIPA Buffer (Cell Signalling, London, UK) containing Halt Protease Inhibitor Single-Use Cocktail (ThermoFisher Scientific, Waltham, MA, USA) and 5 mM N-ethylmaleimide (NEM) (ThermoFisher Scientific, Waltham, MA, USA) to each well and incubating the plate on a platform shaker at medium speed for 10 min at 4°C. Lysates were passed through a 20G1½ 1 mL syringe (BD Biosciences, San Jose, CA, USA) 3 times, transferred to centrifuge tubes and rotated at 15 rpm for 10 min at 4°C. Lysates were centrifuged for 10 min at 15000 rpm and 4°C, 25 µl of lysate was removed for input and the remaining lysate was made up to 1 mL and incubated with the antibody-coupled beads for 18 hr at 4°C with rotation.

Beads were washed 3 times in 500 µl lysis buffer for 10 min at 4°C with 15 rpm rotation. Elution was performed at 95°C for 5 min in 40 µl 1X LDS Sample Buffer (ThermoFisher Scientific, Waltham, MA, USA) with 5% β-mercaptoethanol (Sigma Aldrich, St. Louis, MI, USA). Input
samples (10 µl) were denatured at 95°C for 5 min in 1X LDS Sample Buffer (ThermoFisher Scientific, Waltham, MA, USA) with 5% β-mercaptoethanol (Sigma Aldrich, St. Louis, MI, USA) in a total volume of 20 µl. Eluates and inputs were electrophoresed (10 µl of the eluate and input was loaded for the detection of TDP-43, 13 µl of the eluate and 10 ml of input for the detection of ubiquitin) on NuPAGE 4-12% Bis-Tris gels (ThermoFisher Scientific, Waltham, MA, USA) in NuPAGE MES or MOPS Buffer (ThermoFisher Scientific, Waltham, MA, USA). Protein was transferred onto 0.45 µm nitrocellulose membranes (BioRad, Hercules, CA, USA) using the XCell II Blot Module (ThermoFisher Scientific, Waltham, MA, USA), in 1X Transfer Buffer (ThermoFisher Scientific, Waltham, MA, USA), run at 30V for 75 min (note: gels to be transferred to membranes for blotting of ubiquitin were soaked in transfer buffer for 5 min prior to wet transfer). Membranes were blocked in Tris buffered saline with 0.05% Tween® 20 (TBST) (ThermoFisher Scientific, Waltham, MA, USA) with 5% non-fat dry milk (LabScientific, Danvers, MA, USA) for 1 hr at room temperature, then incubated in primary antibody in TBST overnight at 4°C. Membranes were washed 5 x 5 min in TBST, incubated in secondary antibody in TBST for 1 hr at room temperature, washed 5 x 5 min in TBST and covered in ECL Prime detection reagents (Amersham, Little Chalfont, UK) for 5 min in the dark. Rabbit anti-TDP-43 (1:10,000; Proteintech, Rosemont, IL, USA Cat# 10782-2-AP, RRID: AB_615042) and rabbit anti-ubiquitin (1:1000; Cell Signalling, London, UK Technology, Cat# 3933, RRID: AB_2180538) and goat anti-rabbit HRP (1:5000; EMD Millipore, Burlington, MA, USA Cat# 115-035-146, RRID:AB_11212848) were used.

**Cycloheximide pulse chase**

To examine the stability of TDP-43-YFP, COS-7 cells were seeded at a density of 2.7 x 10^5 cells in a 6-well plate overnight in DMEM with high glucose (ThermoFisher Scientific, Waltham, MA, USA), 10% FBS (Sigma Aldrich, St. Louis, MI, USA) and penicillin-streptomycin (ThermoFisher Scientific, Waltham, MA, USA). The following day, each well was transfected with 2.5 µg plasmid DNA, 2.5 µl PLUS reagent and 7.9 µl LTX in 400 µl OPTIMEM I in DMEM with high glucose and L-glutamine (all ThermoFisher Scientific, Waltham, MA, USA) and 10% FBS (Sigma Aldrich, St. Louis, MI, USA). Cells were treated with 100 µg/mL Cycloheximide (Sigma Aldrich, St. Louis, MI, USA) in DMEM with high glucose and L-glutamine (all ThermoFisher Scientific, Waltham, MA, USA) and 10% FBS (Sigma Aldrich, St. Louis, MI, USA) with penicillin-streptomycin (ThermoFisher Scientific, Waltham, MA, USA)) starting at 24 hr after transfection. The media with DMSO (ThermoFisher Scientific) or 100 µg/mL Cycloheximide (Sigma Aldrich, St. Louis, MI, USA) was replaced every 24 hr during this period. Cells were lysed at 0 hr, 24 hr and 48hr (see paragraph below for cell lysis). To examine the stability of endogenous TDP-43, a 6-well plate was inoculated with COS-7 cells at a seeding density of 5.6x10^5 cells. Cells were grown in DMEM with high glucose and L-glutamine (ThermoFisher Scientific, Waltham, MA, USA) and 10% FBS (Sigma Aldrich, St. Louis, MI, USA) with penicillin-streptomycin (ThermoFisher Scientific, Waltham, MA, USA) in 6-well plates overnight. Cells were treated with 100 µg/mL Cycloheximide (Sigma Aldrich, St. Louis, MI, USA) in in DMEM with high glucose and L-glutamine (ThermoFisher Scientific, Waltham, MA, USA) and 10% FBS (Sigma Aldrich, St. Louis, MI, USA) with penicillin-streptomycin (ThermoFisher Scientific, Waltham, MA, USA) and lysed (see paragraph below)16 hr after drug treatment.
Cells were lysed by adding 300 µl RIPA Buffer (Cell Signalling, London, UK) containing Halt Protease Inhibitor Single-Use Cocktail (ThermoFisher Scientific, Waltham, MA, USA) and 5 mM N-ethylmaleimide (NEM) (ThermoFisher Scientific, Waltham, MA, USA) and incubated on a platform shaker at medium speed for 10 min at 4°C. Lysates were then passed through a 20G1½ 1 mL syringe (BD Biosciences, San Jose, CA, USA) 3 times, transferred to centrifuge tubes for 15 rpm rotation for 10 min at 4°C and centrifuged for 10 min at 15000 rpm and 4°C. Inputs were denatured at 95°C for 5 min in 20 µl 1X LDS Sample Buffer (ThermoFisher Scientific, Waltham, MA, USA) with 5% β-mercaptoethanol (Sigma Aldrich, St. Louis, MI, USA) and run (5 µl) on NuPAGE 4-12% Bis-Tris gels in NuPAGE MES or MOPS buffer (all ThermoFisher Scientific, Waltham, MA, USA). Wet transfer was performed using 0.45 µm nitrocellulose membranes (BioRad) using the XCell II Blot Module (ThermoFisher Scientific, Waltham, MA, USA) in 1X Transfer Buffer (ThermoFisher Scientific, Waltham, MA, USA), run at 20V for 105 minutes. Membranes were blocked in Tris buffered saline with 0.05% Tween® 20 (TBST) (ThermoFisher Scientific, Waltham, MA, USA) with 5% non-fat dry milk (LabScientific, Danvers, MA, USA) for 1 hr at room temperature, then incubated in primary antibody in TBST overnight at 4°C. Membranes were washed 5 x 5 min in TBST, incubated in secondary antibody in TBST for 1 hr at room temperature, washed 5 x 5 min in TBST and covered in ECL Prime detection reagent (Amersham, Little Chalfont, UK) for 5 min in the dark. Rabbit anti-TDP-43 (1:10000; Proteintech, Rosemont, IL, USA, Cat# 10782-2-AP, RRID: AB_615042) and goat anti-rabbit HRP (1:5000; EMD Millipore, Burlington, MA, USA, Cat 115-035-146, RRID: AB_11212848) were used.

Immunofluorescence
Immunofluorescence was carried out in 24-well format. Cells (COS-7 and HEK293T) were seeded at a density of 60,000 cells per well onto glass coverslips (Neuvitro, Vancouver, WA, Canada) in DMEM with high glucose and L-glutamine (ThermoFisher Scientific, Waltham, MA, USA) and 10% FBS (Sigma Aldrich, St. Louis, MI, USA) with penicillin-streptomycin (ThermoFisher Scientific, Waltham, MA, USA) and incubated overnight at 37°C with 5% CO2 and water bath was used for humidification. The following day (~ 18 hr later) each well was transfected with 500 ng of plasmid DNA, 1.75 µL lipofectamine LTX and 0.5 µL PLUS reagent in 100 µL of OPTIMEM I (all ThermoFisher Scientific, Waltham, MA, USA). 21 hr post transfection cells were treated with 10µM MG132 (Sigma Aldrich, St. Louis, MI, USA) and incubated overnight at 37°C in 5% CO2 and water bath was used for humidification. The following day (~ 18 hr later) each well was transfected with 500 ng of plasmid DNA, 1.75 µL lipofectamine LTX and 0.5 µL PLUS reagent in 100 µL of OPTIMEM I (all ThermoFisher Scientific, Waltham, MA, USA). 21 hr post transfection cells were treated with 10µM MG132 (Sigma Aldrich, St. Louis, MI, USA) for the indicated amount of time. Treatment with the DMSO control always matched the longest MG132 treatment. For localization studies in the presence of Tnks-1/2 inhibitors, cells were transfected in the presence of the indicated amount of drug G007-LK and IWR1-endo (both SelleckChem, Houston, TX, USA) and fixed 21 hr post-transfection. Cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) in 50mM HEPES pH7.4, 150mM NaCl, 1mM MgCl2 and 1mM EGTA (All Sigma Aldrich, St. Louis, MI, USA). Fixed cells were permeabilized by 3 sets of 3 min in 100mM PIPES, 1mM MgCl2, 10mM EGTA pH 6.8, and 0.1% Triton-X100 (PEM-T buffer) (All Sigma Aldrich, St. Louis, MI, USA). Cells were blocked in 10% normal donkey serum (Sigma Aldrich, St. Louis, MI, USA) in Tris buffered saline with 0.05% Tween® 20 (TBST) (ThermoFisher Scientific, Waltham, MA, USA). Primary antibodies in TBST (ThermoFisher Scientific, Waltham, MA, USA) were applied overnight at 4°C in a humidified chamber. Cells were washed 3 times in PEM-T buffer (3 min each) and secondary antibody in TBST (ThermoFisher Scientific, Waltham, MA, USA) was applied for 45 min at room temperature and in the dark. Cells were washed 3 times in TBST (3 min each), stained with 1 µg/ml Hoechst-33342 (ThermoFisher Scientific, Waltham,
MA, USA) (15 min), washed in deionized H$_2$O and mounted in prolong diamond (ThermoFisher Scientific, Waltham, MA, USA). All experiments were performed at least three independent times.

Primary antibodies used were rabbit anti-G3BP1 (1 in 1000; ThermoFisher Scientific, Waltham, MA, USA, Cat# PA5-29455, RRID: AB_2546931) and mouse anti-ubiquitin (1 in 300; Cell Signalling Technology, London, UK, Cat# 3936, RRID: AB_331292). Secondary antibodies (all 1 in 500, ThermoFisher Scientific, Waltham, MA, USA) were Goat anti-rabbit Alexa Fluor 647, Cat# A-212245, RRID: AB_2535813; Goat anti-rabbit Alexa Fluor 594, Cat# A11036, RRID:AB_141359; Goat anti-mouse Alexa Fluor 647, Cat# 21236, RRID:AB_141725; Donkey anti mouse Alexa Fluor 594, Cat# 21203 RRID: AB_141633.

**Image acquisition and quantification**

All imaging was performed on fixed cells at 18-23°C on a Leica DMI6000, widefield epifluorescent microscope (Leica Microsystems, Buffalo Grove, IL, USA). To quantify MG132-induced foci 4-5 independent images at 20X were captured. The number of transfected cells were quantified in each image, the number of transfected cells with either nuclear or cytoplasmic foci were counted and the number of cells with nuclear or cytoplasmic foci TDP-43 foci that co-labelled with ubiquitin were counted and a percentage was calculated. For comparing the effect of MG132 on TDP-43-WT-YFP vs TDP-43-AΔTBD-YFP, 139-298 transfected cells were quantified per condition. For comparing the effect of MG132 on TDP-43-WT-GFP, TDP-43-ΔNLS/PBM-GFP, TDP-43-ΔNLS/PBM$_{Δ}$-GFP and TDP-43-ΔNLS/PBM$_{Δ}$A1-GFP, 129-514 transfected cells were quantified per condition. For quantifying the effect of Tnks-1/2 inhibition on TDP-43-GFP localization, 4-5 independent images at 20X were captured at the same exposure time. Cells with diffuse cytoplasmic GFP and/or GFP foci in the cytoplasm were scored as cells with cytoplasmic TDP-43-GFP. Up to 540 transfected cells were quantified per condition. All experiments were at repeated at least 3 independent times and the mean (± s.e.m.) calculated.

**Statistical analysis**

All data points in each graph are mean (± SEM or st. dev.) and the n is a biological repeat. T Tests, one-way ANOVA, two-way ANOVA and multiple comparison tests were performed and are described in each figure legend. Significance was set at p < 0.05, values for asterisks are presented in each legend. All statistical analyses were carried out using Graphpad prism6 software (GraphPad software, San Diego, CA, USA).

**Data availability**

Requests for resources, reagents and further information should be directed to, and will be fulfilled upon reasonable request.
Acknowledgments
We thank members of the Bonini Lab for insightful comments. Robert G. Kalb at Northwestern University for the TDP-43 and LacZ viral amplicons. Racheal Neve, Director of the Massachusetts General Hospital (MGH) Gene Delivery Technology Core for HSV viral production. This work was funded by Target ALS; the Glenn Foundation and NIH 5R01NS073660, R35NS097275 (N.M.B.).

Author contributions
L.M. conceived and designed experiments, performed experiments, analyzed the data, performed statistics, and wrote and edited the manuscript. O.R. performed experiments, analyzed the data and performed statistics and proofread the manuscript. N.M.B conceived experiments, analyzed the data and edited the manuscript.

References
Arai, T., M. Hasegawa, H. Akiyama, K. Ikeda, T. Nonaka, H. Mori, D. Mann, K. Tsuchiya, M. Yoshida, Y. Hashizume, and T. Oda. 2006. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and biophysical research communications. 351:602-611.
Balendra, R., and A.M. Isaacs. 2018. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nature reviews. Neurology. 14:544-558.
Benajiba, L., I. Le Ber, A. Camuzat, M. Lacoste, C. Thomas-Anterion, P. Couratier, S. Legalloc, F. Salachas, D. Hennequin, M. Decousus, L. Lacomblez, E. Guedj, V. Golfiger, W. Camu, B. Dubois, D. Campion, V. Meiningher, A. Brice, C. French, and D. Genetic Research Network on Frontotemporal Lobar Degeneration/Frontotemporal Lobar Degeneration with Motoneuron. 2009. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Annals of neurology. 65:470-473.
Bhardwaj, A., Y. Yang, B. Ueberheide, and S. Smith. 2017. Whole proteome analysis of human tankyrase knockout cells reveals targets of tankyrase-mediated degradation. Nature communications. 8:2214.
Borroni, B., C. Bonvicini, A. Alberici, E. Buratti, C. Agosti, S. Archetti, A. Papetti, C. Stuani, M. Di Luca, M. Gennarelli, and A. Padovani. 2009. Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Hum Mutat. 30:E974-983.
Burguete, A.S., S. Almeida, F.B. Gao, R. Kalb, M.R. Akins, and N.M. Bonini. 2015. GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. Elife. 4:e08881.
Callow, M.G., H. Tran, L. Phu, T. Lau, J. Lee, W.N. Sandoval, P.S. Liu, S. Bheddah, J. Tao, J.R. Lill, J.A. Hongo, D. Davis, D.S. Kirpatrick, P. Polakis, and M. Costa. 2011. Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. Plos one. 6:e22595.
Chang, W., J.N. Dynek, and S. Smith. 2003. TRF1 is degraded by ubiquitin-mediated proteolysis after release from telomeres. Genes & development. 17:1328-1333.
Chen, H.J., S.D. Topp, H.S. Hui, E. Zacco, M. Katarya, C. McLoughlin, A. King, B.N. Smith, C. Troakes, A. Pastore, and C.E. Shaw. 2019. RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy. Brain : a journal of neurology.
Cho-Park, P.F., and H. Steller. 2013. Proteasome regulation by ADP-ribosylation. *Cell*. 153:614-627.

Citarelli, M., S. Teotia, and R.S. Lamb. 2010. Evolutionary history of the poly(ADP-ribose) polymerase gene family in eukaryotes. *BMC Evol Biol*. 10:308.

Combet, C., C. Blanchet, C. Geourjon, and G. Deleage. 2000. NPS@: network protein sequence analysis. *Trends Biochem Sci*. 25:147-150.

Cook, B.D., J.N. Dynek, W. Chang, G. Shostak, and S. Smith. 2002. Role for the Related Poly(ADP-Ribose) Polymerases Tankyrase 1 and 2 at Human Telomeres. *Molecular and cellular biology*. 22:332-342.

Croy, H.E., C.N. Fuller, J. Giannotti, P. Robinson, A.V. Foley, R.J. Yamulla, S. Cosgriff, B.D. Greaves, R.A. von Kleeck, H.H. An, C.M. Powers, J.K. Tran, A.M. Tocker, K.D. Jacob, B.K. Davis, and D.M. Roberts. 2016. The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the beta-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2. *The Journal of biological chemistry*. 291:12747-12760.

DaRosa, P.A., R.E. Klevit, and W. Xu. 2018. Structural basis for tankyrase-RNF146 interaction reveals noncanonical tankyrase-binding motifs. *Protein Sci*. 27:1057-1067.

De Rycker, M., and C.M. Price. 2004. Tankyrase polymerization is controlled by its sterile alpha motif and poly(ADP-ribose) polymerase domains. *Molecular and cellular biology*. 24:9802-9812.

De Rycker, M., R.N. Venkatesan, C. Wei, and C.M. Price. 2003. Vertebrate tankyrase domain structure and sterile alpha motif (SAM)-mediated multimerization. *The Biochemical journal*. 372:87-96.

Duan, Y., A. Du, J. Gu, G. Duan, C. Wang, X. Gui, Z. Ma, B. Qian, X. Deng, K. Zhang, L. Sun, K. Tian, Y. Zhang, H. Jiang, C. Liu, and Y. Fang. 2019. PARylation regulates stress granule dynamics, phase separation, and neurotoxicity of disease-related RNA-binding proteins. *Cell Res*. 29:233-247.

Elden, A.C., H.J. Kim, M.P. Hart, A.S. Chen-Plotkin, B.S. Johnson, X. Fang, M. Armakola, F. Geser, R. Greene, M.M. Lu, A. Padmanabhan, D. Clay-Falcone, L. McCluskey, L. Elman, D. Juhr, P.J. Gruber, U. Rub, G. Auberger, J.Q. Trojanowski, V.M. Lee, V.M. Van Deerlin, N.M. Bonini, and A.D. Gitler. 2010. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. *Nature*. 466:1069-1075.

Fatokun, A.A., V.L. Dawson, and T.M. Dawson. 2014. Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. *Br J Pharmacol*. 171:2000-2016.

Feng, Y., X. Li, L. Ray, H. Song, J. Qu, S. Lin, and X. Lin. 2014. The Drosophila tankyrase regulates Wg signaling depending on the concentration of Daxin. *Cell Signal*. 26:1717-1724.

Floris, G., G. Borghero, A. Cannas, F. Di Stefano, M.R. Murru, D. Corongiu, S. Cuccu, S. Tranquilli, M.V. Cherchi, A. Serra, G. Loi, M.G. Marrosu, A. Chio, and F. Marrosu. 2015. Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations. *Journal of neurology*. 262:375-384.

Gao, F.B., S. Almeida, and R. Lopez-Gonzalez. 2017. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. *The EMBO journal*. 36:2931-2950.
Gitcho, M.A., E.H. Bigio, M. Mishra, N. Johnson, S. Weintraub, M. Mesulam, R. Rademakers, S. Chakraverty, C. Cruchaga, J.C. Morris, A.M. Goate, and N.J. Cairns. 2009. TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. *Acta neuropathologica*. 118:633-645.

Guettler, S., J. LaRose, E. Petsalaki, G. Gish, A. Scotter, T. Pawson, R. Rottapel, and F. Sicheri. 2011. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. *Cell*. 147:1340-1354.

Gupte, R., Z. Liu, and W.L. Kraus. 2017. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. *Genes & development*. 31:101-126.

Hans, F., F.C. Fiesel, J.C. Strong, S. Jackel, T.M. Rasse, S. Geisler, W. Springer, J.B. Schulz, A. Voigt, and P.J. Kahle. 2014. UBE2E ubiquitin-conjugating enzymes and ubiquitin isopeptidase Y regulate TDP-43 protein ubiquitination. *The Journal of biological chemistry*. 289:19164-19179.

Huang, C.C., J.K. Bose, P. Majumder, K.H. Lee, J.T. Huang, J.K. Huang, and C.K. Shen. 2014. Metabolism and mis-metabolism of the neuropathological signature protein TDP-43. *J Cell Sci*. 127:3024-3038.

Huang, S.M., Y.M. Mishina, S. Liu, A. Cheung, F. Stegmeier, G.A. Michaud, O. Charlat, E. Wielllette, Y. Zhang, S. Wiessner, M. Hild, X. Shi, C.J. Wilson, C. Mickanin, V. Myer, A. Fazal, R. Tomlinson, F. Serluca, W. Shao, H. Cheng, M. Shultz, C. Rau, M. Schirle, J. Schlegl, S. Ghidelli, S. Fawell, C. Lu, D. Curtis, M.W. Kirschner, C. Lengauer, P.M. Finan, J.A. Tallarico, T. Bouwmeester, J.A. Porter, A. Bauer, and F. Cong. 2009. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. *Nature*. 461:614-620.

Kabashi, E., P.N. Valdmanis, P. Dion, D. Spiegelman, B.J. McConkey, C. Vande Velde, J.P. Bouchard, L. Lacomblez, K. Pochigaeva, F. Salachas, P.F. Pradat, W. Camu, V. Meininger, N. Dupre, and G.A. Rouleau. 2008. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nature genetics*. 40:572-574.

Kim, S.H., Y. Shi, K.A. Hanson, L.M. Williams, R. Sakasai, M.J. Bowler, and R.S. Tibbetts. 2009. Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1. *The Journal of biological chemistry*. 284:8083-8092.

Klim, J.R., L.A. Williams, F. Limone, I. Guerra San Juan, B.N. Davis-Dusenbery, D.A. Mordes, A. Burberry, M.J. Steinbaugh, K.K. Gamage, R. Kirchner, R. Mocca, S.H. Cassel, K. Chen, B.J. Wainger, C.J. Woolf, and K. Eggan. 2019. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. *Nature neuroscience*. 22:167-179.

Kovacs, G.G., J.R. Murrell, S. Horvath, L. Haraszti, K. Majtenyi, M.J. Molnar, H. Budka, B. Ghetti, and S. Spina. 2009. TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. *Movement disorders : official journal of the Movement Disorder Society*. 24:1843-1847.
Kwong, L.K., D.J. Irwin, A.K. Walker, Y. Xu, D.M. Riddle, J.Q. Trojanowski, and V.M. Lee. 2014. Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins. *Acta neuropathologica communications*. 2:33.

Lee, B.J., A.E. Cansizoglu, K.E. Suel, T.H. Louis, Z. Zhang, and Y.M. Chook. 2006. Rules for nuclear localization sequence recognition by karyopherin beta 2. *Cell*. 126:543-558.

Lee, S.M., S. Asress, C.M. Hales, M. Gearing, J.C. Vizcarra, C.N. Fournier, D.A. Gutman, L.S. Chin, L. Li, and J.D. Glass. 2019. TDP-43 cytoplasmic inclusion formation is disrupted in C9orf72-associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration. *Brain Commun*. 1:fcz014.

Levaot, N., O. Voytyuk, I. Dimitriou, F. Sircoulomb, A. Chandrakumar, M. Deckert, P.M. Krzyzanowski, A. Scotter, S. Gu, S. Janmohamed, F. Cong, P.D. Simoncic, Y. Ueki, J. La Rose, and R. Rottapel. 2011. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. *Cell*. 147:1324-1339.

Li, N., Y. Zhang, X. Han, K. Liang, J. Wang, L. Feng, W. Wang, Z. Songyang, C. Lin, L. Yang, Y. Yu, and J. Chen. 2015. Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growth. *Genes & development*. 29:157-170.

Li, W., A.N. Reeb, B. Lin, P. Subramanian, E.E. Fey, C.R. Knoverek, R.L. French, E.H. Bigio, and Y.M. Ayala. 2017a. Heat Shock-induced Phosphorylation of TAR DNA-binding Protein 43 (TDP-43) by MAPK/ERK Kinase Regulates TDP-43 Function. *The Journal of biological chemistry*. 292:5089-5100.

Li, X., H. Han, M.T. Zhou, B. Yang, A.P. Ta, N. Li, J. Chen, and W. Wang. 2017b. Proteomic Analysis of the Human Tankyrase Protein Interaction Network Reveals Its Role in Pexophagy. *Cell reports*. 20:737-749.

Ling, S.C., M. Polymenidou, and D.W. Cleveland. 2013. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. *Neuron*. 79:416-438.

Liu, Y., W. Duan, Y. Guo, Z. Li, H. Han, S. Zhang, P. Yuan, and C. Li. 2014. A new cellular model of pathological TDP-43: The neurotoxicity of stably expressed CTF25 of TDP-43 depends on the proteasome. *Neuroscience*. 281:88-98.

Lukavsky, P.J., D. Daujotyte, J.R. Tollervey, J. Ule, C. Stuani, E. Buratti, F.E. Baralle, F.F. Damberger, and F.H. Allain. 2013. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. *Nat Struct Mol Biol*. 20:1443-1449.

Mackenzie, I.R., E.H. Bigio, P.G. Ince, F. Geser, M. Neumann, N.J. Cairns, L.K. Kwong, M.S. Forman, J. Ravits, H. Stewart, A. Eisen, L. McClusky, H.A. Kretzschmar, C.M. Monoranu, J.R. Highley, J. Kirby, T. Siddique, P.J. Shaw, V.M. Lee, and J.Q. Trojanowski. 2007. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. *Annals of neurology*. 61:427-434.

Mackenzie, I.R., and M. Neumann. 2016. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. *Journal of neurochemistry*. 138 Suppl 1:54-70.

Mariotti, L., C.M. Templeton, M. Ranes, P. Paracuellos, N. Cronin, F. Beuron, E. Morris, and S. Guettler. 2016. Tankyrase Requires SAM Domain-Dependent Polymerization to Support Wnt-beta-Catenin Signaling. *Molecular cell*. 63:498-513.
Mazroui, R., S. Di Marco, R.J. Kaufman, and I.E. Gallouzi. 2007. Inhibition of the ubiquitin-proteasome system induces stress granule formation. *Molecular biology of the cell*. 18:2603-2618.

McGurk, L., E. Gomes, L. Guo, J. Mojsilovic-Petrovic, V. Tran, R.G. Kalb, J. Shorter, and N.M. Bonini. 2018a. Poly(ADP-Ribose) Prevents Pathological Phase Separation of TDP-43 by Promoting Liquid Demixing and Stress Granule Localization. *Molecular cell*. 71:703-717 e709.

McGurk, L., E. Gomes, L. Guo, J. Shorter, and N. Bonini. 2018b. Poly(ADP-ribose) engages the TDP-43 nuclear-localization sequence to regulate granulo-filamentous aggregation. *Biochemistry*. 57:6923-6926.

McGurk, L., J. Mojsilovic-Petrovic, V.M. Van Deerlin, J. Shorter, R.G. Kalb, V.M. Lee, J.Q. Trojanowski, E.B. Lee, and N.M. Bonini. 2018c. Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis. *Acta neuropathologica communications*. 6:84-95.

McGurk, L., O.M. Rifai, and N.M. Bonini. 2019. Poly(ADP-Ribosylation) in Age-Related Neurological Disease. *Trends Genet*. 35:601-613.

Mishra, M., T. Paunesku, G.E. Woloschak, T. Siddique, L.J. Zhu, S. Lin, K. Greco, and E.H. Bigio. 2007. Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. *Acta neuropathologica*. 114:81-94.

Morrone, S., Z. Cheng, R.T. Moon, F. Cong, and W. Xu. 2012. Crystal structure of a Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate recruitment. *Proceedings of the National Academy of Sciences of the United States of America*. 109:1500-1505.

Nagy, Z., A. Kalousi, A. Forst, M. Koch, B. Fischer, and E. Soutoglou. 2016. Tankyrases Promote Homologous Recombination and Check Point Activation in Response to DSBs. *PLoS genetics*. 12:e1005791.

Naumann, M., A. Pal, A. Goswami, X. Lojewski, J. Japtok, A. Vehlow, M. Naujock, R. Gunther, M. Jin, N. Stanslowsky, P. Reinhardt, J. Sterneckert, M. Frickenhaus, F. Pan-Montojo, E. Storkebaum, I. Poser, A. Freischmidt, J.H. Weishaupt, K. Holzmann, D. Troost, A.C. Ludolph, T.M. Boeckers, S. Liebau, S. Petri, N. Cordes, A.A. Hyman, F. Wegner, S.W. Grill, J. Weis, A. Storch, and A. Hermann. 2018. Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation. *Nature communications*. 9:335.

Neumann, M., L.K. Kwong, A.C. Truax, B. Vanmassenhove, H.A. Kretzschmar, V.M. Van Deerlin, C.M. Clark, M. Grossman, B.L. Miller, J.Q. Trojanowski, and V.M. Lee. 2007. TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. *Journal of neuropathology and experimental neurology*. 66:177-183.

Neumann, M., D.M. Sampathu, L.K. Kwong, A.C. Truax, M.C. Micsenyi, T.T. Chou, J. Bruce, T. Schuck, M. Grossman, C.M. Clark, L.F. McCluskey, B.L. Miller, E. Masliah, I.R. Mackenzie, H. Feldman, W. Feiden, H.A. Kretzschmar, J.Q. Trojanowski, and V.M. Lee. 2006. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science*. 314:130-133.
Nonaka, T., T. Arai, E. Buratti, F.E. Baralle, H. Akiyama, and M. Hasegawa. 2009. Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells. FEBS letters. 583:394-400.

Rippmann, J.F., K. Damm, and A. Schnapp. 2002. Functional characterization of the poly(ADP-ribose) polymerase activity of tankyrase 1, a potential regulator of telomere length. Journal of molecular biology. 323:217-224.

Rulten, S.I., A. Rotheray, R.L. Green, G.J. Grundy, D.A. Moore, F. Gomez-Herreros, M. Hafezparast, and K.W. Caldecott. 2014. PARP-1 dependent recruitment of the amyotrophic lateral sclerosis-associated protein FUS/TLS to sites of oxidative DNA damage. Nucleic Acids Res. 42:307-314.

Sabatelli, M., M. Zollino, A. Conte, A. Del Grande, G. Marangi, M. Lucchini, M. Mirabella, A. Romano, R. Piacentini, G. Bisogni, S. Lattante, M. Luigetti, P.M. Rossini, and A. Moncada. 2015. Primary fibroblasts cultures reveal TDP-43 abnormalities in amyotrophic lateral sclerosis patients with and without SOD1 mutations. Neurobiology of aging. 36:2005 e2005-2005 e2013.

Sbodio, J.I., and N.W. Chi. 2002. Identification of a tankyrase-binding motif shared by IRAP, TAB182, and human TRF1 but not mouse TRF1. NuMA contains this RXXPDG motif and is a novel tankyrase partner. The Journal of biological chemistry. 277:31887-31892.

Scotter, E.L., H.J. Chen, and C.E. Shaw. 2015. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics. 12:352-363.

Scotter, E.L., C. Vance, A.L. Nishimura, Y.B. Lee, H.J. Chen, H. Urwin, V. Sardone, J.C. Mitchell, B. Rogelj, D.C. Rubinsztein, and C.E. Shaw. 2014. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J Cell Sci. 127:1263-1278.

Smith, S., and T. de Lange. 1999. Cell cycle dependent localization of the telomeric PARP, tankyrase, to nuclear pore complexes and centrosomes. J Cell Sci. 112 ( Pt 21):3649-3656.

Smith, S., and T. de Lange. 2000. Tankyrase promotes telomere elongation in human cells. Current biology : CB. 10:1299-1302.

Smith, S., I. Giriat, A. Schmitt, and T. de Lange. 1998. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science. 282:1484-1487.

Sreedharan, J., I.P. Blair, V.B. Tripathi, X. Hu, C. Vance, B. Rogelj, S. Ackerley, J.C. Durnall, K.L. Williams, E. Buratti, F. Baralle, J. de Belleroche, J.D. Mitchell, P.N. Leigh, A. Al-Chalabi, C.C. Miller, G. Nicholson, and C.E. Shaw. 2008. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 319:1668-1672.

Synofzik, M., M.A. Gonzalez, C.M. Lourenco, M. Coutelier, T.B. Haack, A. Rebelo, D. Hannquin, T.M. Strom, H. Prokisch, C. Kernstock, A. Durr, L. Schols, M.M. Lima-Martinez, A. Farooq, R. Schule, G. Stevanin, W. Marques, Jr., and S. Zuchner. 2014. PNPLA6 mutations cause Boucher-Neuhauser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum. Brain : a journal of neurology. 137:69-77.

Taylor, J.P., R.H. Brown, Jr., and D.W. Cleveland. 2016. Decoding ALS: from genes to mechanism. Nature. 539:197-206.

Teloni, F., and M. Altmeyer. 2016. Readers of poly(ADP-ribose): designed to be fit for purpose. Nucleic Acids Res. 44:993-1006.
Van Deerlin, V.M., J.B. Leverenz, L.M. Bekris, T.D. Bird, W. Yuan, L.B. Elman, D. Clay, E.M. Wood, A.S. Chen-Plotkin, M. Martinez-Lage, E. Steinbart, L. McCluskey, M. Grossman, M. Neumann, I.L. Wu, W.S. Yang, R. Kalb, D.R. Galasko, T.J. Montine, J.Q. Trojanowski, V.M. Lee, G.D. Schellenberg, and C.E. Yu. 2008. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. The Lancet. Neurology. 7:409-416.

van Eersel, J., Y.D. Ke, A. Gladbach, M. Bi, J. Gotz, J.J. Kril, and L.M. Ittner. 2011. Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. PloS one. 6:e22850.

Voronkov, A., D.D. Holsworth, J. Waaler, S.R. Wilson, B. Ekblad, H. Perdreau-Dahl, H. Dinh, G. Drewes, C. Hopf, J.P. Morth, and S. Krauss. 2013. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. Journal of medicinal chemistry. 56:3012-3023.

Vyas, S., I. Matic, L. Uchima, J. Rood, R. Zaja, R.T. Hay, I. Ahel, and P. Chang. 2014. Family-wide analysis of poly(ADP-ribose) polymerase activity. Nature communications. 5:4426.

Walker, A.K., K.Y. Soo, V. Sundaramoorthy, S. Parakh, Y. Ma, M.A. Farg, R.H. Wallace, P.J. Crouch, B.J. Turner, M.K. Horne, and J.D. Atkin. 2013. ALS-associated TDP-43 induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation. PloS one. 8:e81170.

Wang, X., H. Fan, Z. Ying, B. Li, H. Wang, and G. Wang. 2010. Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neuroscience letters. 469:112-116.

Wang, Z., O. Tacchelly-Benites, E. Yang, and Y. Ahmed. 2016. Dual Roles for Membrane Association of Drosophila Axin in Wnt Signaling. PLoS genetics. 12:e1006494.

White, M.A., E. Kim, A. Duffy, R. Adalbert, B.U. Phillips, O.M. Peters, J. Stephenson, S. Yang, F. Massenzio, Z. Lin, S. Andrews, A. Segonds-Pichon, J. Metterville, L.M. Saksida, R. Mead, R.R. Ribchester, Y. Barhomi, T. Serre, M.P. Coleman, J.R. Fallon, T.J. Bussey, R.H. Brown, Jr., and J. Sreedharan. 2018. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nature neuroscience. 21:552-563.

Winton, M.J., L.M. Igaz, M.M. Wong, L.K. Kwong, J.Q. Trojanowski, and V.M. Lee. 2008. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. The Journal of biological chemistry. 283:13302-13309.

Yang, E., O. Tacchelly-Benites, Z. Wang, M.P. Randall, A. Tian, H. Benchabane, S. Freemantle, C. Pikielny, N.S. Tolwinski, E. Lee, and Y. Ahmed. 2016. Wnt pathway activation by ADP-ribosylation. Nature communications. 7:11430.

Zhang, Y., S. Liu, C. Mickanin, Y. Feng, O. Charlat, G.A. Michaud, M. Schirle, X. Shi, M. Hild, A. Bauer, V.E. Myer, P.M. Finan, J.A. Porter, S.M. Huang, and F. Cong. 2011. RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nature cell biology. 13:623-629.

Zhang, Y.J., T.F. Gendron, Y.F. Xu, L.W. Ko, S.H. Yen, and L. Petrucelli. 2010. Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragments. Molecular neurodegeneration. 5:33.
**Figures**

**A.**

Cortical neurons isolated from Sprague Dawley embryos (E16-E18) were seeded in 24-well plate format at a density of 100,000 neurons. After 15-18 days in vitro (DIV) neurons were virally infected with either HSV-LacZ or HSV-TDP-43 and treated with DMSO or G007-LK. Neurons were fixed and immunostained 7d post infection (DPI). See Fig. S2 for expanded images.

**B.**

Neurons were immunolabelled for the neuronal marker Tubulin β-III chain (green) and counterstained with Hoechst (blue). Arrows indicate neurons.

**C.**

Viral infection with HSV-TDP-43 at 5 moi resulted in a significant loss in cortical neurons compared to the HSV-LacZ control. Co-treatment with the Tnks-1/2 inhibitor G007-LK (at 1 μM and 10 μM) significantly suppressed TDP-43-associated neuronal loss. Graph represents the mean (st. dev) from the same pregnant female. One-way ANOVA ($p < 0.0001$) and Dunnett’s test. See Supplementary Fig 1B-C for 2 other independent biological repeats. NS: not significant. Asterisks, significant. ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

**Figure 1:** The Tankyrase-1/2 inhibitor G007-LK reduces TDP-43-associated loss of rat primary cortical neurons.
Figure 2. TDP-43 and Tankyrase-1/2 interact via a Tankyrase-binding domain.

A. Endogenous Tnks-1/2 co-immunoprecipitated with endogenous TDP-43 in COS-7 cells. Experiment repeated 3 independent times.

B. Endogenous Tnks-1/2 co-immunoprecipitated with human TDP-43-WT-YFP in COS-7 cells. Experiment repeated 4 independent times.
C. TDP-43 conserved protein domains. NTD, N-terminal domain, NLS, nuclear localization sequence; PBM: PAR-binding motif, RRM, RNA recognition motif; PrLD, prion-like domain. The putative Tankyrase-binding domain is amino acids 165-170.

D. TDP-43 amino acids 165-170 are evolutionarily conserved among Homo sapiens (H.s.), Mus musculus (M.m), Danio rerio (D.r.), Xenopus tropicalis (X.t.), Drosophila melanogaster (D.m.) and Stronglyocentrotus purpuratus (S.p.). Black asterisks indicate the evolutionary conserved amino acids. The aspartic acid at position 169 is mutated to glycine (D169G) in a case of sporadic ALS (Kabashi et al., 2008).

E. Alignment of TDP-43 amino acids 165-170 to Tankyrase-binding domains in Tax1-binding protein 1 (TXBP151), Telomere-repeat binding factor 1 (TRF-1), Ubiquitin specific peptidase 25 (USP25), Nuclear mitotic apparatus protein (NuMA), 182 kDa Tankyrase-binding protein (TAB182), Homeobox B2 (Hox-B2), L-type calcium channel (L-type), protein phosphatase 1 (PP1), Insulin-responsive aminopeptidase (IRAP) (Sbodio and Chi, 2002) (asterisks indicate conserved amino acids in this set of proteins).

F. Deletion of the predicted TBD in TDP-43 prevents endogenous Tnks-1/2 co-immunoprecipitating with human TDP-43-WT-YFP in COS-7 cells. Experiment was repeated 6 independent times.

G. A series of TDP-43-YFP constructs were generated with the amino acids in the TBD mutated to alanine highlighted in red.

H. Mutation of either H166 or I168 to alanine (red asterisks) was sufficient to abolish the interaction between endogenous Tnks-1/2 and TDP-43-YFP in COS-7 cells, while mutation of R165, M167, D169 or G170 to alanine had little to no effect. Experiment repeated 3 independent times.

I. The previously reported NMR structure of the RNA recognition motifs (RRMs) of TDP-43 binding to UG-rich RNA (4BS2) (Lukavsky et al., 2013). The TBD was identified using FirstGlance in Jmol. The yellow halos mark the structure of each amino acid in the TBD.

J. The amino acids (H166 and I168) in the TBD that are critical for the interaction between Tnks-1/2 and TDP-43 are marked with a red asterisk and those that have no to little effect on the interaction with Tnks-1/2 when mutated to alanine are marked with a white asterisk.
Figure 3. Tnks-1/2 regulates the degradation of TDP-43.

A. Cells were treated with cycloheximide (CHX) in the presence of vehicle (DMSO) or the Tnks-1/2 inhibitor XAV939 (10 µM). The levels of endogenous TDP-43 were assessed by immunoblot.

B. Endogenous TDP-43 was less stable in the presence of XAV939 compared to control (DMSO). Mean (st. dev.) of 3 independent experiments. Two-way ANOVA ($p < 0.0001$) and Sidak’s multiple comparison test. Asterisks, significant. ** $p < 0.01$.

C. Cells expressing TDP-43-WT-YFP and TDP-43-ΔTBD-YFP were treated with the protein synthesis inhibitor cycloheximide (CHX), and protein levels were determined by immunoblot for TDP-43.

D. TDP-43-ΔTBD-YFP was less stable than TDP-43-WT-YFP upon cycloheximide (CHX) treatment. Mean (st. dev) of 3 independent experiments. Two-way ANOVA ($p < 0.0001$) and Sidak’s multiple comparison test.

E. Cells expressing TDP-43-YFP (-WT, -ΔTBD, -R165A, -H166A, -M167A, -I168A, -D169A and -G1870A were treated with protein synthesis inhibitor cycloheximide (CHX) and protein levels were determined by immunoblot.

F. Mutations in the TBD of TDP-43-YFP that abolish the interaction with Tnks-1/2 (ΔTBD, H166A or I168A) led to a reduction in protein stability compared TDP-43-WT. By contrast, the stability of TDP-43 with mutations in the TBD that do no effect the interaction with Tnks-1/2 (R165A, M167A, D169A or G170A) was no different from the stability of TDP-43-WT. NS: not significant. Asterisks, significant. ** $p < 0.01$, ***$p < 0.001$, **** $p < 0.0001$. 
**Figure 4:** Tnks-1/2 regulates the ubiquitination of TDP-43.

A-B. Cells expressing TDP-43-WT-YFP or TDP-43-ΔTBD-YFP were exposed to vehicle (DMSO) or 10 µM MG123. (A) Immunoprecipitated TDP-43-YFP or (B) total cell lysates were immunoblotted for ubiquitin and TDP-43.

C. A significant increase in MG132-induced ubiquitination of TDP-43-ΔTBD-YFP is detected at an earlier time point compared to TDP-43-WT-YFP, indicating that TDP-43-ΔTBD is more rapidly ubiquitinated than TDP-43-WT. Mean (st. dev.) of 3 independent experiments. Two-way ANOVA ($p < 0.0273$) and an uncorrected Fisher’s exact test for significance. NS: not significant. Asterisks, significant. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

D-E. Cells expressing TDP-43-WT-YFP were exposed to vehicle (DMSO), MG132 alone, or MG132 and the Tnks-1/2 inhibitor G007-LK (1 µM or 10 µM). Immunoblots of (D) immunoprecipitated TDP-43-WT and (E) total cell lysate probed for ubiquitin and TDP-43.

F. Co-treatment with G007-LK and MG132 significantly increased the levels of ubiquitinated TDP-43-WT-YFP compared to MG132 alone. Mean (st. dev.) of 3 independent experiments. One-way ANOVA ($p = 0.0013$) followed by a Tukey’s test for significance. NS: not significant. Asterisks, significant. * $p < 0.05$, ** $p < 0.01$. 
Figure 5. Deletion of the TBD promotes MG132-induced nuclear ubiquitination of TDP-43.

A. COS-7 cells expressing TDP-43-WT-YFP and TDP-43-ΔTBD-YFP were treated with vehicle or MG132 for the indicated time periods. Cells were fixed and immunolabelled for the cytoplasmic protein G3BP1 (yellow) and ubiquitin (magenta), and counterstained with Hoechst (blue). Both TDP-43-YFP proteins formed nuclear foci upon proteasome inhibition (green). Nuclear foci of TDP-43-ΔTBD were co-labelled with ubiquitin by 2 hr of MG132 treatment, whereas TDP-43-WT co-labelled with ubiquitin only by 4 hr of MG132 treatment. Nuclei outlined in white dashed line.
B. Cells were quantified for the presence of nuclear TDP-43-YFP foci and for nuclear TDP-43-YFP foci that co-labelled with ubiquitin. Both TDP-43 variants proteins (WT and ΔTBD) formed nuclear foci in response to MG132 treatment. Cells were quantified for the presence of nuclear TDP-43-YFP foci that co-labeled with ubiquitin. A significant increase in nuclear TDP-43-ΔTBD foci co-labelled with ubiquitin was detected at an earlier time point compared to TDP-43-WT (2 hr vs 4 hr). Mean (s.e.m.) of 3 independent experiments (± s.e.m.). Two-way ANOVA (left graph: \( p < 0.0001 \), right graph \( p < 0.0001 \)) and unpaired T tests. NS: not significant. Asterisks, significant. * \( p < 0.05 \), ** \( p < 0.01 \), *** \( p < 0.001 \).

C. Cells were quantified for the presence of cytoplasmic TDP-43-YFP foci and for cytoplasmic TDP-43-YFP foci that co-labelled with ubiquitin. No increase in cytoplasmic foci formation was observed for either TDP-43-WT or TDP-43-ΔTBD or for cytoplasmic TDP-43-WT or TDP-43-ΔTBD foci co-labelled with ubiquitin in response to MG132 treatment. Mean (s.e.m.) of 3 experiments. Two-way ANOVA (right graph: \( p < 0.1931 \) and left graph \( p = 0.672 \)). NS: not significant.
**Figure 6.** MG132-treatment led to the formation of nuclear TDP-43 foci that co-label with Ubiquitin.

A. TDP-43-WT-GFP diffusely localizes to the nucleus while TDP-43-ΔNLS/PBM-GFP is diffusely cytoplasmic. Addition of an exogenous NLS from either TDP-43 (-ΔNLS/PBM<sub>TDP-43</sub>) or hnRNPA1 (-ΔNLS/PBM<sub>A1</sub>) localizes TDP-43-ΔNLS/PBM-GFP to the nucleus. COS-7 cells were treated with DMSO for 3 hr, fixed and counterstained with Hoechst.

B. Treatment with 10 μM MG132 (3 hr) led to the formation of nuclear TDP-43-WT-GFP foci that co-labelled with ubiquitin, while TDP-43-ΔNLS/PBM-GFP in the cytoplasm remained diffuse. TDP-43-ΔNLS/PBM re-localized to the nucleus by an exogenous NLS either from TDP-43 (-ΔNLS/PBM<sub>TDP-43</sub>) or hnRNPA1 (-ΔNLS/PBM<sub>A1</sub>) formed MG132-induced nuclear foci that co-labelled with ubiquitin. These data suggest that mutation in the NLS/PBM does not inhibit foci formation. COS-7 cells immunolabelled for ubiquitin, fixed and counterstained with Hoechst.

C. TDP-43-GFP localized to the nucleus (-WT, -ΔNLS/PBM<sub>TDP-43</sub> and -Δ NLS/PBM<sub>A1</sub>) forms foci that co-label with ubiquitin upon treatment with 10 μM MG132 (3 hr). Cells were quantified for the presence of nuclear TDP-43-GFP foci and the presence of nuclear TDP-43-GFP foci that co-labelled with ubiquitin. Mean of 3 independent experiments (s.e.m.), two-way-ANOVA (both graphs: \( p < 0.0001 \)) and Tukey’s test. NS: not significant. Asterisks, significant. * \( p < 0.05 \), ** \( p < 0.01 \), **** \( p < 0.0001 \).

D. Treatment with 10 μM MG132 (3 hr) did not increase the percentage of cells with cytoplasmic TDP-43-GFP foci that co-labelled with ubiquitin. Mean of 3 independent experiments (s.e.m.), two-way-ANOVA (right graph: \( p = 0.7789 \), left graph: \( p = 0.6644 \)). NS: not significant.

E. Cells expressing TDP-43-GFP (-WT, -ΔNLS/PBM or -ΔNLS/ PBM<sub>TDP-43</sub>) were exposed to vehicle (DMSO) or MG132 (10 μM). Immunoblots of (top panel) immunoprecipitated TDP-43-GFP or (bottom panel) total cell lysate for ubiquitin and TDP-43.

F. Upon MG132 treatment, the level of ubiquitinated TDP-43-GFP relative to total protein levels was significantly lower for TDP-43-ΔNLS/PBM compared to TDP-43-WT and TDP-43-ΔNLS/PBM<sub>TDP-43</sub>. Mean of 3 independent experiments (st. dev), two-way ANOVA (\( p < 0.0001 \)) and a Dunnett’s test. NS: not significant. Asterisks, significant. ** \( p < 0.01 \).
Figure 7. Tnks-1/2 inhibition promotes nuclear localization of TDP-43.

A. Treatment with Tnks-1/2 inhibitor G007-LK (10 μM) reduced cytoplasmic accumulation of TDP-43-WT-GFP. Cells were immunostained for the cytoplasmic protein G3BP1 (magenta) and counterstained with Hoechst (blue). Inner dashed line marks the nuclear boundary and outer solid line marks the cytoplasmic boundary.

B. Treatment of cells with Tnks-1/2 inhibitors G007-LK and IWR1-endo led to a significant reduction in the percentage of cells with cytoplasmic TDP-43-GFP. Percentage of cells with cytoplasmic TDP-43-GFP with a diffuse GFP signal or GFP-positive puncta were quantified. Mean (s.e.m.) of 3 independent experiments, one-way ANOVA (p = 0.0032) and a Tukey’s tests. NS: not significant. Asterisks, significant. ** p < 0.01.

C. Treatment with the Tnks-1/2 inhibitor XAV939 led to a significant reduction in the percentage of cells with cytoplasmic TDP-43-GFP. Graph represents the mean (s.e.m.) of 3 independent experiments, one-way ANOVA (p < 0.0004) and a Holm’s-Sidak test. Asterisks, significant. * p < 0.05.
Figure 8: Model. 

Model for effects of Tnks-1/2 to modulate the subcellular localization of TDP-43. The data show that Tnks-1/2 promotes cytoplasmic accumulation of TDP-43, thereby inhibiting access of TDP-43 to the nuclear proteasome. In this way, Tnks-1/2 stabilizes TDP-43 in the cytoplasm. In human disease, accumulation of TDP-43 in the cytoplasm is observed in affected brain cells of >95% of ALS cases and ~45% of FTD cases. Thus, therapeutic inhibition of Tnks-1/2 in ALS/FTD may maintain TDP-43 in the nucleus where misfolded or mutated forms of the protein can be degraded by the nuclear proteasome.
Figure S1: Rat primary cortical neurons and quantification of neuronal cultures infected with TDP-43<subHSV</sub> or LacZ<subHSV</sub> and treated with either vehicle control or the Tnks-1/2 inhibitor G007-LK.

A. Representative images of rat primary cortical neuron cultures at 18 days in vitro (DIV). Cultures were immunolabelled with the neuronal marker Tubulin β-III chain (green) and the glial marker GFAP (magenta) and counterstained with Hoechst (blue).

B-C. Viral infection with HSV-TDP-43 at 5 moi resulted in a significant loss in cortical neurons compared to the HSV-LacZ control. Co-treatment with the Tnks-1/2 inhibitor G007-LK (at 1 µM and 10 µM) significantly suppressed TDP-43-associated neuronal loss. Each graph is data from an independent biological repeat. Graph represents the mean (st. dev). One-way ANOVA (p < 0.0001) and Dunnet’s test. NS: not significant. Asterisks, significant. * p < 0.05, *** p < 0.001, **** p < 0.0001.

Related to Figure 1.
Figure S2: Rat primary cortical neurons infected with TDP-43_{HSV} or LacZ_{HSV} and treated with either vehicle control or the Tnks-1/2 inhibitors G007-LK.

Cortical neurons isolated from Sprague Dawley embryos (E16-E18) were virally infected with either HSV-LacZ or HSV-TDP-43 and treated with DMSO or G007-LK after 15-18 days in
vitro (DIV). 7d post infection (DPI), neurons were fixed and immunostained with the neuronal marker Tubulin β-III chain and counterstained with Hoechst. These are the same images presented in Fig. 7 here the images have been expanded and the Hoechst and Tubulin β-III chain signals have been separated.

Related to Figure 1.
Figure S3. TDP-43 co-immunoprecipitates with Tankyrase-1/2.

A. Endogenous Tnks-1/2 co-immunoprecipitated with endogenous TDP-43 in HEK-293T cells.

B. Endogenous Tnks-1/2 co-immunoprecipitated with TDP-43-WT-YFP expressed in HEK-293T cells.

C. The consensus of the Tankyrase-binding motif (TBD), RxxΦDG (where x represents any amino acid and Φ is a small hydrophobic amino acid) (Guettler et al., 2011; Sbodio and Chi, 2002), was aligned to TDP-43 using the PATTINPROT search engine (Combet et al., 2000). Table lists all regions with sequence similarity to the TBD identified in TDP-43. The region with highest amino acid identity to the TBM (amino acids 165-170) was mutated in this study.

D. TDP-43-WT-YFP and TDP-43-ΔTBD-YFP both co-immunoprecipitated with endogenous TDP-43 in COS-7 cells.

E. Endogenous Tnks-1/2 co-immunoprecipitated with TDP-43-D169G-YFP expressed in COS-7 cells.

Related to Figure 2.
**Figure S4: Mean levels of TDP-43-YFP**

Cells expressing TDP-43-YFP were treated with cycloheximide and TDP-43-YFP levels were measured by immunoblot. The table presents the mean and standard deviation from 3 independent experimental repeats.

Related to Figure 3.
Figure S5: Treatment with XAV939 enhances MG132-induced ubiquitination of TDP-43-YFP.

A-B: Cells expressing TDP-43-WT-YFP were exposed to vehicle (DMSO), MG132 alone, or MG132 and the Tnks-1/2 inhibitor XAV939 (1 µM). (A) Immunoprecipitated TDP-43-YFP and (B) total cell lysates immunoblotted for ubiquitin and TDP-43.

C: Co-treatment with XAV939 and MG132 significantly increased the levels of ubiquitinated TDP-43-YFP compared to MG132 alone. Mean (st. dev.) of 3 independent experiments. One-way ANOVA ($p = 0.0013$) followed by a Holm-Sidak’s test. Asterisks, significant. * $p < 0.05$, **$p < 0.01$.

Related to Figure 4.
Figure S6: Treatment with XAV939 alone does not lead to ubiquitination of TDP-43.

A-B. Cells expressing TDP-43-WT-YFP were exposed to vehicle (DMSO), 1 µM XAV939 or MG132 10 µM. (A) Immunoprecipitated TDP-43-YFP and (B) total cell lysate immunoblotted for ubiquitin and TDP-43. Treatment with XAV939 alone did not lead to the ubiquitination of TDP-43; treatment with MG132 increased ubiquitination of TDP-43.

Related to Figure 4.
Figure S7. Treatment with MG132 leads to selective accumulation of TDP-43 in the nucleus of both COS-7 cells and HEK-293T cells.

A. The NLS from TDP-43 (TDP-43-ΔPBM) and the NLS from hnRNPA1 (TDP-43-ΔPBMₐ₁) was inserted immediately upstream of the stop codon of TDP-43-ΔNLS/PBM. The encoded amino acids inserted into each plasmid construct are indicated. TDP-43 domains: NTD, N-terminal domain (amino acids 1-80); NLS, nuclear localization sequence; PBM: PAR-binding motif; RRM, RNA recognition motif; PrLD: prion-like domain; the amino acids in red in the NLS/PBM were mutated to alanine, this mutation (ΔPBM/NLS) inhibits nuclear import of TDP-43.

B. COS-7 and HEK-293T cells expressing TDP-43-WT-GFP or TDP-43-ΔPBM-GFP were exposed to a control (DMSO) or 10 µM MG132 for 5 hr. TDP-43-WT-GFP formed
nuclear foci upon MG132 treatment, while TDP-43-ΔPBM remained diffuse in the cytoplasm. Cells were fixed and counterstained with Hoechst.

C. In both COS-7 cells and HEK-293T cells, treatment with 10 µM MG132 for 3 hr and 5 hr led to a significant increase in the percentage of cells with nuclear foci of TDP-43-WT-GFP. Mean (s.e.m.) of 3 independent experiments, two-way ANOVA ($p < 0.0001$) and a Tukey’s tests was used for significance. NS: not significant. Asterisks, significant. **** $p < 0.0001$.

D. In both COS-7 cells and HEK-293T cells, treatment with 10 µM MG132 for 3 hr and 5 hr did not lead TDP-43-GFP foci in the cytoplasm. Mean (s.e.m.) of 3 independent experiments, two-way ANOVA ($p < 0.053$) and a Tukey’s tests was used for significance. NS: not significant.

Related to Figure 6.
Figure S8: MG132 leads to accumulation of G3BP1-labelled foci in the cytoplasm.

A. COS-7 cells treated with vehicle (DMSO) or 10 µM MG132 were fixed and immunolabeled with G3BP1 (yellow) and counterstained with Hoechst (blue).

B. The percentage of cells with G3BP1-labelled foci in the cytoplasm was calculated. MG132 (10 µM) for 3 hr lead to a significant increase in G3BP1-labelled foci in the cytoplasm. These data are consistent with previous data that demonstrate that G3BP1-labeled stress granules form after 3 hr of treatment with 10 µM MG132 (Mazroui et al., 2007).

Related to Figure 6.

Supplemental references

Combet, C., C. Blanchet, C. Geourjon, and G. Deleage. 2000. NPS@: network protein sequence analysis. Trends Biochem Sci. 25:147-150.

Guettler, S., J. LaRose, E. Petsalaki, G. Gish, A. Scotter, T. Pawson, R. Rottapel, and F. Sicheri. 2011. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell. 147:1340-1354.

Mazroui, R., S. Di Marco, R.J. Kaufman, and I.E. Gallouzi. 2007. Inhibition of the ubiquitin-proteasome system induces stress granule formation. Molecular biology of the cell. 18:2603-2618.

Sbodio, J.I., and N.W. Chi. 2002. Identification of a tankyrase-binding motif shared by IRAP, TAB182, and human TRF1 but not mouse TRF1. NuMA contains this RXXPDG motif and is a novel tankyrase partner. The Journal of biological chemistry. 277:31887-31892.